import Redaction from "./Redaction";
import Head from 'next/head';
import './styles.css';

export default function Home() {
    return (
        <div>
            <Head>
                <link
                    href='http://fonts.googleapis.com/css?family=Roboto:400,100,100italic,300,300italic,400italic,500,500italic,700,700italic,900italic,900'
                    rel='stylesheet' type='text/css'/>
            </Head>
            <main className="max-w-[60rem] mx-auto p-4 px-7 bg-white text-justify">
                <div className="head">
                    <div className="logo">
                        <svg viewBox="0 0 5111 1233" fill="none" xmlns="http://www.w3.org/2000/svg"
                             className="logo">
                            <path
                                d="M820.999 411.522C820.999 638.228 637.321 821.905 410.615 821.905V1232.29H820.999C1047.7 1232.29 1231.38 1048.61 1231.38 821.905C1231.38 595.2 1047.7 411.522 820.999 411.522Z"
                                fill="url(#paint0_linear_4050_228)"></path>
                            <path
                                d="M820.998 411.515V0.900635H0V411.284C0 637.989 183.678 821.667 410.383 821.667V411.284H820.767L820.998 411.515Z"
                                fill="#1D1E21"></path>
                            <path
                                d="M2021 591.794C2096.73 550.728 2141.08 480.422 2141.08 399.932C2141.08 245.194 2032.5 156.655 1843.1 156.655H1523.94V1068.16H1860.35C2054.19 1068.16 2174.43 966.319 2174.43 802.546C2174.43 703.33 2118.74 627.768 2020.84 591.958L2021 591.794ZM1834.4 534.137H1669.15V285.604H1834.4C1933.94 285.604 1990.94 330.941 1990.94 409.952C1990.94 488.964 1933.94 534.301 1834.4 534.301V534.137ZM1669.15 663.085H1851.81C1961.54 663.085 2024.45 712.529 2024.45 798.604C2024.45 884.679 1961.54 939.051 1851.81 939.051H1669.15V663.249V663.085Z"
                                fill="#1D1E21"></path>
                            <path d="M2406.86 156.651H2260.5V1068.16H2406.86V156.651Z" fill="#1D1E21"></path>
                            <path
                                d="M3109.75 761.148C3121.42 649.119 3092.5 548.095 3028.11 476.64C2970.62 412.741 2887.99 377.588 2795.68 377.588C2607.92 377.588 2471.58 523.784 2471.58 725.173C2471.58 937.569 2603.32 1080.32 2799.46 1080.32C2960.27 1080.32 3076.24 989.641 3109.59 837.859L3112.22 825.868H2967.99L2966.18 833.424C2945.98 915.557 2884.22 962.537 2796.83 962.537C2694.82 962.537 2632.23 894.202 2620.08 769.854H3108.77L3109.75 760.983V761.148ZM2793.21 491.753C2887.01 491.753 2947.62 557.13 2956.49 667.024H2621.72C2637.49 556.966 2700.9 491.753 2793.05 491.753H2793.21Z"
                                fill="#1D1E21"></path>
                            <path
                                d="M3517.13 377.754C3437.79 377.754 3366.5 413.728 3317.06 477.627V390.238H3180.55V1068.16H3325.76V686.901C3325.76 583.25 3388.02 508.017 3473.6 508.017C3583.49 508.017 3606.66 598.527 3606.66 674.582V1068.16H3751.87V632.365C3751.87 475.328 3662.01 377.918 3517.3 377.918L3517.13 377.754Z"
                                fill="#1D1E21"></path>
                            <path
                                d="M4312.01 479.76C4263.88 414.547 4192.1 377.752 4110.79 377.752C3930.26 377.752 3809.03 519.02 3809.03 729.115C3809.03 939.21 3933.05 1080.48 4110.79 1080.48C4195.88 1080.48 4270.78 1042.04 4320.72 973.706V1068.16H4457.22V156.651H4312.01V479.76ZM4135.59 949.066C4026.85 949.066 3959.17 864.798 3959.17 729.115C3959.17 593.432 4026.85 508.014 4135.59 508.014C4244.34 508.014 4312.01 593.925 4312.01 726.651C4312.01 859.377 4241.05 949.066 4135.59 949.066Z"
                                fill="#1D1E21"></path>
                            <path
                                d="M4909.94 677.208L4798.08 656.018C4721.53 641.727 4693.11 619.058 4693.11 572.571C4693.11 522.799 4740.25 491.753 4816.14 491.753C4899.59 491.753 4953.47 535.283 4960.37 608.217L4961.19 617.087H5101.31L5100.49 606.41C5088.82 465.306 4979.42 377.588 4814.99 377.588C4650.56 377.588 4551.84 460.378 4551.84 583.577C4551.84 685.914 4620.34 753.263 4749.95 778.395L4856.72 798.272C4937.21 814.041 4964.31 835.396 4964.31 883.032C4964.31 958.266 4868.71 966.315 4827.64 966.315C4732.53 966.315 4670.77 919.006 4666.17 842.623L4665.68 833.424H4525.23L4526.22 844.102C4539.36 994.24 4648.43 1080.32 4825.34 1080.32C5002.26 1080.32 5111 998.675 5111 861.842C5111 761.969 5045.29 701.519 4910.43 677.044L4909.94 677.208Z"
                                fill="#1D1E21"></path>
                            <defs>
                                <linearGradient id="paint0_linear_4050_228" x1="1151.57" y1="1235.06" x2="542.706"
                                                y2="684.263" gradientUnits="userSpaceOnUse">
                                    <stop stop-color="#1D1E21" stop-opacity="0"></stop>
                                    <stop offset="0.82" stop-color="#1D1E21"></stop>
                                </linearGradient>
                            </defs>
                        </svg>
                    </div>
                    <h1>A Comprehensive Review of TLR4 Agonists: Therapeutic Applications Beyond Oncology and
                        Vaccines</h1>
                </div>
                <div className="index">
                    <a className="h2" href="#1-introduction">1. Introduction</a>
                    <a className="h2" href="#2-mechanism-of-action-of-tlr4-agonists">2. Mechanism of Action of TLR4
                        Agonists</a>
                    <a className="h3" href="#2-1-structure-and-function-of-tlr4">2.1 Structure and Function of TLR4</a>
                    <a className="h3" href="#2-2-role-of-md-2-and-cd14-in-tlr4-activation">2.2 Role of MD-2 and CD14 in
                        TLR4 Activation</a>
                    <a className="h3" href="#2-3-tlr4-signaling-pathways">2.3 TLR4 Signaling Pathways</a>
                    <a className="h3" href="#2-4-tlr4-agonists-and-antagonists">2.4 TLR4 Agonists and Antagonists</a>
                    <a className="h3" href="#2-5-tlr4-in-immunity-and-infection-resistance">2.5 TLR4 in Immunity</a>
                    <a className="h2" href="#3-tlr4-agonists-in-infectious-diseases">3. TLR4 Agonists in Infectious
                        Diseases</a>
                    <a className="h3" href="#3-1-role-of-tlr4-agonists-in-enhancing-host-resistance-to-infections">3.1.
                        Role of TLR4 Agonists in Enhancing Host Resistance to Infections</a>
                    <a className="h3" href="#3-2-potential-therapeutic-applications-in-treating-sepsis">3.2. Potential
                        Therapeutic Applications in Treating Sepsis</a>
                    <a className="h3" href="#3-4-combination-of-tlr4-agonists-with-antibiotics-for-synergistic-effects">3.3.
                        Combination of TLR4 Agonists with Antibiotics for Synergistic Effects</a>
                    <a className="h3" href="#3-5-tlr4-agonists-in-the-treatment-of-nosocomial-and-viral-infections">3.4.
                        TLR4 Agonists in the Treatment of Nosocomial and Viral Infections</a>
                    <a className="h2" href="#4-tlr4-agonists-in-autoimmune-and-inflammatory-diseases">4. TLR4 Agonists
                        in Autoimmune and Inflammatory Diseases</a>
                    <a className="h3" href="#4-1-tlr4-agonists-in-neuroinflammatory-disorders">4.1. TLR4 Agonists in
                        Neuroinflammatory Disorders</a>
                    <a className="h3" href="#4-2-tlr4-agonists-in-autoimmune-diseases">4.2. TLR4 Agonists in Autoimmune
                        Diseases</a>
                    <a className="h3" href="#4-3-tlr4-agonists-in-metabolic-and-cardiovascular-diseases">4.3. TLR4
                        Agonists in Metabolic and Cardiovascular Diseases</a>
                    <a className="h2" href="#5-tlr4-agonists-in-neurological-disorders">5. TLR4 Agonists in Neurological
                        Disorders</a>
                    <a className="h3" href="#5-1-neurodegenerative-diseases">5.1. Neurodegenerative Diseases</a>
                    <a className="h3" href="#5-2-acute-neurological-conditions">5.2. Acute Neurological Conditions</a>
                    <a className="h2" href="#6-tlr4-agonists-in-metabolic-and-cardiovascular-diseases">6. TLR4 Agonists
                        in Metabolic and Cardiovascular Diseases</a>
                    <a className="h3" href="#6-1-metabolic-disorders">6.1. Metabolic Disorders</a>
                    <a className="h3" href="#6-2-cardiovascular-diseases">6.2. Cardiovascular Diseases</a>
                    <a className="h2" href="#7-tlr4-agonists-in-allergy-and-asthma">7. TLR4 Agonists in Allergy and
                        Asthma</a>
                    <a className="h3" href="#7-1-mechanisms-of-action-in-asthma">7.1. Mechanisms of Action in Asthma</a>
                    <a className="h3" href="#7-2-therapeutic-potential-and-clinical-evidence">7.2. Therapeutic Potential
                        and Clinical Evidence</a>
                    <a className="h3" href="#7-3-role-in-conditions-like-allergic-rhinitis-and-atopic-dermatitis">7.3.
                        Role in Conditions like Allergic Rhinitis and Atopic Dermatitis</a>
                    <a className="h3" href="#7-4-clinical-trial-data-and-outcomes">7.4. Clinical Trial Data and
                        Outcomes</a>
                    <a className="h2" href="#8-future-directions">8. Future Directions</a>
                    <a className="h3" href="#1-safety-and-efficacy-of-tlr4-agonists">8.1. Safety and Efficacy of TLR4
                        Agonists</a>
                    <a className="h3" href="#8-2-discovery-and-development-of-novel-tlr4-agonists">8.2. Discovery and
                        Development of Novel TLR4 Agonists</a>
                    <a className="h3" href="#8-3-advances-in-delivery-systems">8.3. Advances in Delivery Systems</a>
                    <a className="h3" href="#8-4-emerging-technologies-and-methodologies">8.4. Emerging Technologies and
                        Methodologies</a>
                    <a className="h3" href="#8-5-challenges-and-solutions-in-tlr4-agonist-development">8.5. Challenges
                        and Solutions in TLR4 Agonist Development</a>
                    <a className="h3" href="#8-6-new-therapeutic-applications-and-personalized-medicine">8.6. New
                        Therapeutic Applications and Personalized Medicine</a>
                    <a className="h2" href="#9-conclusion">9. Conclusion</a>
                    <a className="h2" href="#bibliography">Bibliography</a>

                </div>

                <h2 id="1-introduction">1. Introduction</h2>
                <p>Toll-like receptor 4 (TLR4) agonists are molecules that activate TLR4, a key receptor in the innate
                    immune system. TLR4 recognizes diverse structures like lipopolysaccharides (LPS), peptides,
                    proteins,
                    and small molecules, triggering downstream signaling pathways such as MyD88 and TRIF. These pathways
                    activate transcription factors like NF-kB and interferon-regulating factors, initiating an immune
                    response. The identification of TLR4 agonists requires demonstrating specific TLR4 activation and
                    interactions with TLR4 and MD-2.</p>
                <p>The discovery of TLR4 agonists began with LPS and later included other molecules like paclitaxel and
                    Ni2+ ions. Structural biology and molecular biology studies have been crucial in understanding the
                    interactions between these agonists and the TLR4/MD-2 complex. This research has facilitated the
                    development of synthetic and purified TLR4 agonists, ensuring specificity in activation and avoiding
                    contamination.</p>
                <p>TLR4 agonists are vital in medical research, enhancing immune responses and being used in vaccines
                    and
                    therapies for infectious diseases, cancer, and autoimmune disorders. For instance, lipid A mimetics
                    like E6020 and monophosphoryl lipid A (MPL) are used as vaccine adjuvants, promoting the production
                    of
                    pro-inflammatory cytokines. The ability of TLR4 agonists to modulate immune responses underscores
                    their potential in treating various diseases.</p>
                <p>TLR4 agonists have a broad therapeutic potential, enhancing immune responses and modulating
                    inflammation. They are crucial in vaccine development, acting as potent adjuvants that enhance both
                    humoral and cell-mediated immunity. For example, co-encapsulation of TLR4 and TLR7/8 agonists in
                    liposomal formulations improves early IgG2a antibody titers and Th1-type humoral immunity, essential
                    for effective vaccination strategies.</p>
                <p>In oncology, TLR4 agonists modulate the tumor microenvironment and enhance anti-tumor immune
                    responses.
                    They target tumor-associated macrophages (TAMs), activating them to adopt an antitumor M1 phenotype,
                    which can improve the efficacy of cancer immunotherapies. TLR4 agonists, when used with other
                    therapeutic agents like immune checkpoint inhibitors, offer a synergistic approach to overcoming
                    resistance and enhancing patient outcomes.</p>
                <p>Beyond oncology and vaccines, TLR4 agonists have potential in managing infectious, chronic
                    inflammatory, and autoimmune diseases. They enhance host resistance to infections and serve as
                    adjuvants in vaccines for infectious diseases. Additionally, TLR4 agonists show promise in treating
                    neuroinflammatory disorders and autoimmune diseases by modulating inflammatory cytokine production
                    and
                    immune responses. This review will focus on these broader applications, exploring the mechanisms by
                    which TLR4 agonists can treat a wide range of diseases, highlighting their versatility and potential
                    in disease management.</p>
                <h2 id="2-mechanism-of-action-of-tlr4-agonists">2. Mechanism of Action of TLR4 Agonists</h2>
                <h3 id="2-1-structure-and-function-of-tlr4">2.1 Structure and Function of TLR4</h3>
                <p>Toll-like receptor 4 (TLR4) is a critical component of the innate immune system, functioning as a
                    pattern recognition receptor (PRR) that identifies pathogen-associated molecular patterns (PAMPs)
                    and
                    damage-associated molecular patterns (DAMPs) [27]. Structurally, TLR4 is composed of an
                    extracellular
                    domain, a transmembrane domain, and a cytoplasmic Toll/Interleukin-1 receptor (TIR) domain. The
                    extracellular domain is characterized by leucine-rich repeats (LRRs) that facilitate the recognition
                    of ligands such as lipopolysaccharides (LPS) from Gram-negative bacteria [21]. The binding of LPS to
                    TLR4 is mediated through a complex with the co-receptor MD-2, which directly interacts with the
                    lipid
                    A moiety of LPS, a component essential for TLR4 activation [21, 38]. The crystal structure of the
                    TLR4/MD-2/LPS complex has been resolved at 3.1 Å, revealing the intricate interactions that
                    facilitate
                    receptor dimerization and subsequent signal transduction [38].</p>
                <p>The functional domains of TLR4 play distinct roles in its signaling mechanism. The extracellular LRR
                    domain is responsible for ligand recognition and binding, while the transmembrane domain anchors the
                    receptor to the cell membrane. Upon ligand binding, the TIR domain in the cytoplasmic region
                    undergoes
                    dimerization, which is crucial for the recruitment of adapter proteins such as MyD88 and TRIF [21].
                    This dual signaling pathway allows TLR4 to initiate a broad range of immune responses, including the
                    activation of transcription factors like NF-κB and the production of pro-inflammatory cytokines
                    [21].
                    The ability of TLR4 to signal through both MyD88-dependent and TRIF-dependent pathways distinguishes
                    it from other TLRs, underscoring its versatility and importance in immune regulation [21].</p>
                <p>TLR4 is expressed in a variety of tissues, reflecting its widespread role in immune surveillance and
                    response. It is predominantly found on the surface of immune cells such as macrophages, dendritic
                    cells, and neutrophils, but it is also present in non-immune cells including endothelial cells and
                    adipocytes [27]. This broad expression pattern enables TLR4 to detect and respond to microbial
                    infections and tissue damage across different physiological contexts. For instance, in the central
                    nervous system, TLR4 expression is upregulated in response to amyloid β oligomers, contributing to
                    neuroinflammatory processes observed in neurodegenerative diseases [57]. The ubiquitous presence of
                    TLR4 across various tissues highlights its essential role in maintaining immune homeostasis and
                    orchestrating effective defense mechanisms against a wide array of pathogens and stress signals.</p>
                <h3 id="2-2-role-of-md-2-and-cd14-in-tlr4-activation">2.2 Role of MD-2 and CD14 in TLR4 Activation</h3>
                <p>The activation of Toll-like receptor 4 (TLR4) is a complex process that requires the involvement of
                    co-receptors, particularly myeloid differentiation factor 2 (MD-2) and CD14. MD-2 is a crucial
                    component that binds directly to lipopolysaccharide (LPS), the prototypical ligand for TLR4, through
                    its hydrophobic pocket. This binding is essential for the dimerization of TLR4, which is a
                    prerequisite for downstream signaling. Structural studies have shown that the LPS-MD-2 complex forms
                    a
                    large hydrophobic pocket that facilitates the oligomerization of TLR4, leading to the activation of
                    signaling pathways [38]. The interaction between MD-2 and TLR4 is highly specific, with certain
                    residues in MD-2 being critical for the formation of the TLR4-MD-2 complex, as demonstrated by
                    alanine-scanning mutagenesis studies [21]. This interaction is not only pivotal for LPS recognition
                    but also for the overall stability and surface expression of TLR4 [29].</p>
                <p>CD14, a glycosylphosphatidylinositol-anchored protein, plays a significant role in the initial
                    recognition and transport of LPS to MD-2. CD14 can exist in both membrane-bound and soluble forms,
                    both of which enhance the cellular cytokine response to LPS [42]. CD14 binds to LPS and shuttles it
                    to
                    MD-2, facilitating the formation of the TLR4-MD-2-LPS complex. This process is crucial for the
                    sensitivity of TLR4 to picomolar amounts of LPS, as CD14 extends the recognition capability of TLR4
                    from LPS monomers to aggregates [21]. The importance of CD14 in ligand recognition is further
                    highlighted by studies showing that the uptake of certain ligands, such as CnB, is significantly
                    reduced in CD14-deficient cells [42]. Additionally, CD14 is required for MyD88-independent LPS
                    signaling, underscoring its diverse roles in immune signaling [21].</p>
                <p>The formation of the TLR4-MD-2-CD14 complex is a critical step in the activation of TLR4-mediated
                    signaling pathways. Upon ligand binding, the TLR4-MD-2-LPS complex undergoes dimerization, which
                    induces the dimerization of the cytosolic TIR domains of TLR4. This dimerization recruits adapter
                    proteins such as MyD88 and TRIF, initiating a cascade of signaling events that lead to the
                    transcriptional regulation of several thousand genes [21]. The involvement of CD14 in this process
                    is
                    not limited to LPS; it also plays a role in the recognition and transport of other ligands, such as
                    NA6, which is recognized by TLR4 on the surface of intestinal epithelial cells and sentinel cells in
                    the lamina propria [29]. Thus, the coordinated action of MD-2 and CD14 is essential for the
                    efficient
                    activation of TLR4 and the subsequent immune response.</p>
                <h3 id="2-3-tlr4-signaling-pathways">2.3 TLR4 Signaling Pathways</h3>
                <p>TLR4 signaling is initiated through two primary pathways: the MyD88-dependent and TRIF-dependent
                    pathways, each involving distinct adaptor proteins and downstream signaling molecules. The
                    MyD88-dependent pathway is the primary signaling route for most TLRs, including TLR4, and is crucial
                    for the rapid activation of pro-inflammatory responses. Upon TLR4 activation, MyD88 recruits
                    downstream signaling molecules, leading to the activation of transcription factors such as NF-κB and
                    AP-1, which subsequently induce the expression of inflammatory cytokines and chemokines [9]. This
                    pathway also involves the activation of mitogen-activated protein kinases (MAPKs), which play a
                    critical role in the transcriptional regulation of TLR genes [6]. Additionally, MyD88 has been shown
                    to regulate apoptosis in monocytic cells, highlighting its multifaceted role in immune responses
                    [57].</p>
                <p>The TRIF-dependent pathway, on the other hand, is unique to TLR3 and TLR4 and is essential for the
                    induction of type I interferons and the expression of interferon-inducible genes. TRIF recruits
                    downstream signaling molecules such as TBK1 and IKKε, leading to the activation of transcription
                    factors like IRF3 and NF-κB [16]. This pathway is particularly important for antiviral responses and
                    the production of type I interferons. Studies have shown that the immunomodulatory effects of MPLA,
                    a
                    TLR4 agonist, are mediated preferentially through TRIF, and the activation of PI3K-Akt signaling by
                    MPLA is also TRIF-dependent [46]. Furthermore, TRIF-dependent signaling has been implicated in the
                    prevention of sepsis-induced ERK activation, underscoring its role in modulating immune responses
                    during infections [46].</p>
                <p>Both MyD88- and TRIF-dependent pathways converge on several key downstream signaling molecules and
                    transcription factors that mediate the immune response. For instance, the activation of mTOR, a
                    critical metabolic signaling protein, is induced through overlapping contributions of both MyD88 and
                    TRIF pathways, and is essential for the metabolic reprogramming associated with MPLA-induced
                    infection
                    resistance [11]. Additionally, the activation of NF-κB and IRF pathways by TLR4 agonists such as
                    rSIP
                    and FLH is dependent on both MyD88 and TRIF, indicating the redundancy and overlap in these
                    signaling
                    pathways [9]. The intricate network of interactions between these pathways and their downstream
                    effectors highlights the complexity of TLR4 signaling and its pivotal role in orchestrating immune
                    responses.</p>
                <h3 id="2-4-tlr4-agonists-and-antagonists">2.4 TLR4 Agonists and Antagonists</h3>
                <p>TLR4 agonists can be broadly categorized into natural and synthetic types. Natural agonists include
                    lipopolysaccharides (LPS) and lipid A, which are components of the outer membrane of Gram-negative
                    bacteria and are well-known for their potent immunostimulatory properties [21]. Synthetic TLR4
                    agonists, such as E6020 and αGlcN(1↔1)αMan-based lipid A mimetics, have been developed to mimic the
                    activity of natural agonists without structural similarity to LPS, offering new avenues for
                    immunotherapeutic development [7]. These synthetic agonists can activate TLR4/MD-2 complexes and
                    have
                    been evaluated as vaccine adjuvants due to their ability to induce tailored pro-inflammatory
                    responses
                    [7]. The chemical structure of these agonists, particularly the orientation and length of lipid
                    chains, plays a crucial role in their activity, with some variants exhibiting species-specific
                    TLR4-dependent activities [7].</p>
                <p>In contrast, TLR4 antagonists are designed to inhibit TLR4 signaling and are being developed for the
                    treatment of various inflammatory diseases, including asthma, arteriosclerosis, type 2 diabetes, and
                    autoimmune disorders [2]. The mechanisms of action of TLR4 antagonists involve blocking the
                    dimerization and formation of the hexameric receptor complex, which is essential for TLR4 activation
                    [7]. For instance, tetraacylated lipid IVa acts as an antagonist at human TLR4 (hTLR4) but as an
                    agonist at mouse TLR4 (mTLR4), highlighting the importance of binding orientation within the MD-2
                    binding cleft [7]. Additionally, antagonists can interfere with ionic interactions between lipid A
                    phosphate groups and positively charged side chains in MD-2 and TLR4, further preventing receptor
                    activation [7].</p>
                <p>Comparatively, TLR4 agonists and antagonists exhibit distinct mechanisms and therapeutic
                    applications.
                    Agonists are primarily used to enhance immune responses, making them valuable as vaccine adjuvants
                    and
                    in the treatment of infections and cancer [38]. On the other hand, antagonists aim to dampen
                    excessive
                    inflammatory responses, providing therapeutic benefits in chronic inflammatory and autoimmune
                    diseases
                    [2]. The development of both types of compounds involves a deep understanding of the structural
                    biology of TLR4 and its co-receptors, MD-2 and CD14, to ensure specificity and efficacy [21]. The
                    ongoing research and development of novel TLR4 modulators continue to expand the potential
                    therapeutic
                    applications of these compounds, offering promising strategies for managing a wide range of
                    diseases.</p>
                <h3 id="2-5-tlr4-in-immunity-and-infection-resistance">2.5 TLR4 in Immunity</h3>
                <p>Toll-like receptor 4 (TLR4) plays a pivotal role in the innate immune system, serving as a primary
                    sensor for pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns
                    (DAMPs). TLR4 is predominantly expressed on the surface of innate immune cells such as macrophages
                    and
                    dendritic cells, where it recognizes lipopolysaccharides (LPS) from Gram-negative bacteria [20][23].
                    Upon binding to LPS, TLR4, in conjunction with its co-receptor MD-2, initiates a signaling cascade
                    that leads to the activation of nuclear factor kappa B (NF-κB) and the production of
                    pro-inflammatory
                    cytokines [25]. This rapid response is crucial for the immediate defense against invading pathogens,
                    highlighting TLR4&#39;s essential role in innate immunity [37].</p>
                <p>Beyond its role in innate immunity, TLR4 also significantly influences adaptive immune responses. The
                    activation of TLR4 on dendritic cells (DCs) leads to their maturation and the subsequent priming of
                    naïve T cells, which is essential for the development of antigen-specific adaptive immunity [5].
                    TLR4
                    signaling can polarize DCs to induce either Th1 or Th2 responses, depending on the context and the
                    nature of the pathogen [55]. This dual capability allows TLR4 to tailor the immune response to
                    effectively combat a wide range of pathogens, thereby bridging innate and adaptive immunity [38].
                    Moreover, TLR4 activation has been shown to enhance the production of immunoglobulins, such as IgG,
                    which are critical for long-term immunity [37].</p>
                <p>TLR4&#39;s role in pathogen recognition and clearance is multifaceted. It not only detects bacterial
                    endotoxins but also recognizes various other microbial components and endogenous danger signals
                    [2][40]. This broad recognition spectrum enables TLR4 to initiate a comprehensive immune response
                    that
                    includes the production of interferons and other cytokines, which help in controlling infections and
                    promoting pathogen clearance [23]. Additionally, TLR4 signaling can modulate the function of other
                    immune cells, such as macrophages and neutrophils, further enhancing the body&#39;s ability to
                    eliminate pathogens [37]. Overall, TLR4 is a crucial component of the immune system, orchestrating
                    both immediate and long-term responses to ensure effective pathogen recognition and clearance.</p>
                <h2 id="3-tlr4-agonists-in-infectious-diseases">3. TLR4 Agonists in Infectious Diseases</h2>
                <h3 id="3-1-role-of-tlr4-agonists-in-enhancing-host-resistance-to-infections">3.1. Role of TLR4 Agonists
                    in Enhancing Host Resistance to Infections</h3>
                <p>TLR4 agonists, particularly monophosphoryl lipid A (MPLA), have been shown to significantly enhance
                    host resistance to a wide range of pathogens by reprogramming macrophage metabolism and improving
                    phagocyte recruitment and function. This resistance is mediated through TLR4/mTOR signaling, which
                    boosts both glycolysis and oxidative phosphorylation in macrophages [10]. The activation of TLR4 by
                    MPLA induces a metabolic shift in macrophages, characterized by increased glycolysis and
                    mitochondrial
                    respiration, which are essential for the enhanced antimicrobial functions of these cells [10]. This
                    metabolic reprogramming is crucial for the macrophages&#39; ability to clear infections and reduce
                    the
                    severity of inflammatory responses [47].</p>
                <p>MPLA primes macrophages, enhancing their antimicrobial functions through metabolic reprogramming.
                    This
                    reprogramming involves a delayed induction of mitochondrial biogenesis, which supports the recovery
                    of
                    oxidative metabolism following initial aerobic glycolysis [11]. The activation of TLR4 leads to
                    increased recruitment of phagocytes and improved macrophage function, which are essential for
                    effective host defense against infections. For instance, MPLA-primed macrophages exhibit increased
                    phagocytic and respiratory burst capacity, which are critical for the clearance of pathogens such as
                    S. aureus and C. albicans [10]. This enhanced antimicrobial function is supported by the overlapping
                    and redundant contributions of MyD88- and TRIF-dependent signaling pathways, with mTOR playing a
                    central role in this metabolic programming [11].</p>
                <p>Furthermore, TLR4 agonists have been shown to induce resistance to systemic infections by augmenting
                    efferocytosis and providing organ protection during infections. The role of TLR4 agonists in
                    reprogramming the innate immune response through MyD88- and TRIF-dependent pathways is
                    well-documented, with MyD88 being particularly important for driving TLR-mediated training of innate
                    immunity [10]. This reprogramming not only enhances the host&#39;s ability to clear infections but
                    also reduces the severity of inflammatory responses, making TLR4 agonists like MPLA promising
                    candidates for therapeutic applications in treating infectious diseases [47]. The ability of TLR4
                    agonists to enhance host resistance to infections underscores their potential as valuable tools in
                    the
                    fight against a wide range of pathogens.</p>
                <h3 id="3-2-potential-therapeutic-applications-in-treating-sepsis">3.2. Potential Therapeutic
                    Applications
                    in Treating Sepsis</h3>
                <p>TLR4 agonists, particularly monophosphoryl lipid A (MPLA), have shown significant promise in treating
                    sepsis by mitigating renal dysfunction and metabolic acidosis. Sepsis pathophysiology often involves
                    an uncontrolled TLR4-mediated cytokine storm, leading to severe inflammation and metabolic
                    disturbances, including acidosis. MPLA, a nontoxic TLR4 agonist, has been demonstrated to protect
                    against sepsis-induced renal tubule dysfunction by enhancing the HCO3 absorption capacity of the
                    medullary thick ascending limb (MTAL) in the kidneys. This protective effect is mediated through the
                    activation of a TRIF-dependent PI3K-Akt signaling pathway, which suppresses sepsis- and LPS-induced
                    ERK activation that otherwise inhibits HCO3 absorption [46]. Consequently, MPLA pretreatment not
                    only
                    prevents the decrease in basal HCO3 absorption rate but also attenuates the enhanced inhibition of
                    HCO3 absorption by LPS, thereby improving systemic acid-base balance in septic mice [46].</p>
                <p>The efficacy of MPLA in improving renal function and systemic acid-base balance during sepsis is
                    further supported by its ability to enhance plasma HCO3 concentration and reduce serum creatinine
                    levels, a marker of kidney dysfunction. Studies have shown that MPLA pretreatment in septic mice
                    leads
                    to a marked increase in plasma HCO3 concentration, correlating directly with improved HCO3
                    absorptive
                    capacity in the MTAL [46]. Additionally, the use of PI3K inhibitors, such as wortmannin, eliminates
                    the protective effects of MPLA on MTAL HCO3 absorption and plasma HCO3 concentration, underscoring
                    the
                    critical role of the PI3K-Akt pathway in mediating these effects [46]. These findings highlight the
                    potential of MPLA to serve as a therapeutic agent that not only protects renal function but also
                    addresses the systemic metabolic disturbances associated with sepsis.</p>
                <p>Despite the failure of clinical trials with TLR4 antagonists, the potential of nontoxic TLR4 agonists
                    like MPLA remains significant. MPLA has been shown to enhance antimicrobial responses and improve
                    long-term survival rates in sepsis models, making it a promising candidate for sepsis management
                    [46].
                    By targeting key cell signaling pathways, such as ERK and PI3K, MPLA mitigates sepsis-induced
                    dysfunction and offers a multifaceted approach to sepsis treatment. The ability of MPLA to reprogram
                    immune responses and protect against renal and systemic complications of sepsis underscores its
                    therapeutic potential and warrants further investigation in clinical settings [46].</p>
                <h3 id="3-4-combination-of-tlr4-agonists-with-antibiotics-for-synergistic-effects">3.3. Combination of
                    TLR4 Agonists with Antibiotics for Synergistic Effects</h3>
                <p>Combining TLR4 agonists with antibiotics has shown promising synergistic effects in enhancing immune
                    responses and reducing bacterial burdens. This approach leverages the innate immune system&#39;s
                    ability to recognize and respond to pathogens, potentially reducing the required doses of
                    antibiotics
                    and accelerating recovery. Mechanistically, the synergy between TLR4 agonists and antibiotics
                    involves
                    the co-activation of MyD88 and TRIF pathways, which are crucial for robust immune responses. For
                    instance, the co-delivery of TLR4 and TLR7/8 agonists has been demonstrated to enhance IL-12p70
                    production and Th1 responses, which are essential for effective pathogen clearance [33]. This dual
                    activation can mimic the simultaneous detection of cell wall components and nucleic acids of a
                    pathogen, driving a more comprehensive immune response [33].</p>
                <p>Preclinical evidence supports the efficacy of combining TLR4 agonists with antibiotics in treating
                    bacterial infections. In a mouse model of brucellosis, the administration of lipo-CRX, a TLR4
                    agonist,
                    in combination with the antibiotic ampicillin significantly reduced the bacterial burden in the
                    spleen, although the effect in the lungs was less pronounced [48]. This combination treatment was
                    more
                    effective than either agent alone, suggesting that TLR4 agonists can enhance the efficacy of
                    suboptimal antibiotic treatments [48]. Such findings indicate that TLR4 agonists can be particularly
                    useful in scenarios where antibiotic resistance is prevalent, as they can potentiate the effects of
                    existing antibiotics and improve survival rates in infection models [48].</p>
                <p>However, the combination of TLR4 agonists with antibiotics is not without risks. One significant
                    concern is the potential for immune overactivation, which could lead to cytokine storms and other
                    adverse inflammatory responses [11]. While the benefits of reduced antibiotic doses and accelerated
                    recovery are compelling, careful consideration of the immune system&#39;s balance is crucial to
                    avoid
                    detrimental effects. For example, the use of TLR4 agonists in treating nosocomial infections must be
                    carefully managed to prevent excessive inflammation while still enhancing resistance to infections
                    [11]. Overall, the combination of TLR4 agonists with antibiotics holds great promise but requires
                    meticulous optimization to maximize therapeutic benefits while minimizing risks.</p>
                <h3 id="3-5-tlr4-agonists-in-the-treatment-of-nosocomial-and-viral-infections">3.4. TLR4 Agonists in the
                    Treatment of Nosocomial and Viral Infections</h3>
                <p>TLR4 agonists, particularly monophosphoryl lipid A (MPLA), have shown significant promise in the
                    treatment of nosocomial infections by enhancing the host&#39;s immune response and resistance to
                    pathogens. Nosocomial infections, which are a major concern in healthcare settings due to their
                    association with antibiotic-resistant organisms, can be effectively managed using TLR4 agonists.
                    Studies have demonstrated that MPLA-primed mice exhibit broad resistance to common nosocomial
                    pathogens such as Pseudomonas aeruginosa and Staphylococcus aureus, as well as fungal pathogens like
                    Candida albicans [11]. This resistance is attributed to the enhanced recruitment of neutrophils to
                    infection sites and improved bacterial clearance, which are critical for combating these infections
                    [49]. Furthermore, MPLA has been shown to protect against sepsis-induced transport inhibition in the
                    medullary thick ascending limb (MTAL) of the kidney, highlighting its potential in managing severe
                    infections [46].</p>
                <p>In addition to their efficacy against bacterial infections, TLR4 agonists also play a crucial role in
                    enhancing resistance to viral infections. For instance, prophylactic treatment with TLR ligands has
                    been shown to boost host immunity against avian influenza virus in chickens, leading to the
                    activation
                    of various immune pathways and the production of antiviral molecules [6]. This suggests that TLR4
                    agonists could be employed to enhance immune responses against viral infections in humans as well.
                    Moreover, activating TLR4 on macrophages has been demonstrated to inhibit the replication of
                    influenza
                    virus H4N6 and laryngotracheitis virus, further supporting the potential of TLR4 agonists in
                    managing
                    viral infections [6]. These findings underscore the importance of TLR4 agonists in modulating immune
                    responses to provide broad-spectrum protection against both bacterial and viral pathogens.</p>
                <p>Clinical data support the use of TLR4 agonists in reducing the severity of infections and improving
                    outcomes, particularly in high-risk patient populations such as those who are critically ill or
                    immunocompromised. MPLA, for example, has been employed clinically as a vaccine adjuvant and has
                    shown
                    potential as an immunotherapeutic agent to enhance resistance to infections [11]. Case studies have
                    demonstrated the efficacy of MPLA in preventing nosocomial infections in hospitalized patients,
                    highlighting its potential applications in clinical settings [11]. However, further research is
                    needed
                    to optimize TLR4 agonist formulations for clinical use and to fully understand the molecular
                    mechanisms underlying their immunomodulatory effects. This will be crucial for developing effective
                    therapeutic strategies that leverage TLR4 agonists to manage infections in vulnerable patient
                    populations.</p>
                <h2 id="4-tlr4-agonists-in-autoimmune-and-inflammatory-diseases">4. TLR4 Agonists in Autoimmune and
                    Inflammatory Diseases</h2>
                <h3 id="4-1-tlr4-agonists-in-neuroinflammatory-disorders">4.1. TLR4 Agonists in Neuroinflammatory
                    Disorders</h3>
                <p>Neuroinflammation is a complex process involving the activation of immune cells within the central
                    nervous system (CNS), including microglia, astrocytes, and peripheral immune cells. This process is
                    regulated by various signaling pathways, among which Toll-like receptor 4 (TLR4) plays a significant
                    role. TLR4, in conjunction with its co-receptors MD-2 and CD14, recognizes pathogen-associated
                    molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs), leading to the
                    activation
                    of downstream signaling cascades that result in the production of pro-inflammatory cytokines and
                    chemokines [57]. This inflammatory response is essential for maintaining neuroplasticity and
                    homeostasis; however, dysregulation can lead to chronic neuroinflammation, contributing to the
                    pathogenesis of various neurodegenerative and neuroinflammatory disorders [52].</p>
                <p>In the context of multiple sclerosis (MS), a chronic inflammatory demyelinating autoimmune disease of
                    the CNS, TLR4 agonists have shown potential therapeutic benefits. MS is primarily mediated by
                    effector
                    T cells directed against myelin sheath antigens, leading to sensory, autonomic, cognitive, and motor
                    function deficits [58]. Studies have demonstrated that modulating the gut microbiome, which
                    influences
                    immune responses, could offer new avenues for MS treatment [58]. Additionally, TLR4 agonists like
                    monophosphoryl lipid A (MPL) have been shown to enhance the clearance of amyloid-β (Aβ) deposits and
                    reduce neuroinflammation in Alzheimer&#39;s disease (AD) models, suggesting a broader applicability
                    in
                    neuroinflammatory conditions [57]. These findings underscore the potential of TLR4 agonists in
                    modulating immune responses and reducing neurodegeneration in diseases like MS.</p>
                <p>Preclinical and clinical evidence supports the use of TLR4 agonists in neuroinflammatory disorders.
                    For
                    instance, MPL has been shown to increase cognitive test scores and reduce Aβ deposits in AD model
                    mice, indicating its efficacy in mitigating neuroinflammatory pathology [57]. Furthermore, synthetic
                    TLR4 agonists such as E6020 and its analogs have demonstrated significant immunostimulatory effects
                    in
                    vitro and in vivo, including the induction of pro-inflammatory cytokines and enhanced immune
                    responses
                    [57]. These studies highlight the promise of TLR4 agonists in treating neuroinflammatory disorders.
                    However, further research is needed to fully understand their mechanisms of action and to ensure
                    their
                    safety and efficacy in clinical settings. The ongoing development of novel TLR4 agonists and
                    advances
                    in delivery systems will be crucial in overcoming current challenges and realizing their therapeutic
                    potential [57].</p>
                <h3 id="4-2-tlr4-agonists-in-autoimmune-diseases">4.2. TLR4 Agonists in Autoimmune Diseases</h3>
                <p>TLR4 agonists play a complex role in modulating autoimmune responses, often acting as a double-edged
                    sword. On one hand, TLR4 activation can enhance immune responses against pathogens, but on the
                    other,
                    it can exacerbate autoimmune conditions by promoting inflammation. In multiple sclerosis (MS), for
                    instance, TLR4 activation has been shown to regulate autoimmune responses that lead to
                    neuroinflammation and neuronal death. Th17 and Th1 cells, which are implicated in MS, can cross the
                    blood-brain barrier and become activated in a TLR4-dependent manner, leading to the secretion of
                    pro-inflammatory cytokines such as IL-6 and IL-23. These cytokines stimulate microglia, resulting in
                    neuroinflammatory reactions that damage neurons [57]. Similarly, TLR4 activation in peripheral blood
                    mononuclear cells (PBMCs) can lead to the breakdown of immunological tolerance through nonspecific
                    activation of myelin-specific T cells, further contributing to MS pathogenesis [1].</p>
                <p>In addition to MS, TLR4 agonists have been implicated in other autoimmune diseases such as rheumatoid
                    arthritis (RA) and systemic lupus erythematosus (SLE). In RA, endosomal TLRs, including TLR4, are
                    involved in regulating the production of autoantibodies and the progression of clinical disease [1].
                    High expression of TLR3 to TLR9 on T cells in SLE patients has been correlated with disease
                    activity,
                    suggesting a significant role for TLR4 in the pathogenesis of this condition [58]. The activation of
                    TLR4 in these diseases often leads to the production of pro-inflammatory cytokines and the expansion
                    of pathogenic Th17 cell subsets, which are known to contribute to tissue damage and disease
                    progression [1].</p>
                <p>Efficacy and safety considerations are paramount when exploring the therapeutic potential of TLR4
                    agonists in autoimmune diseases. While TLR4 agonists can potentially modulate immune responses to
                    restore tolerance, their pro-inflammatory effects pose significant risks. For instance, the higher
                    production of IL-1β, IL-6, and IL-23 by monocytes and dendritic cells in response to TLR4 agonists
                    can
                    favor the induction and expansion of pathogenic Th17 cells, exacerbating autoimmune conditions [1].
                    Therefore, clinical trials and long-term monitoring are essential to ensure that the therapeutic
                    benefits of TLR4 agonists outweigh their potential risks. Future research should focus on developing
                    strategies to selectively modulate TLR4 signaling pathways to maximize therapeutic efficacy while
                    minimizing adverse effects.</p>
                <h3 id="4-3-tlr4-agonists-in-metabolic-and-cardiovascular-diseases">4.3. TLR4 Agonists in Metabolic and
                    Cardiovascular Diseases</h3>
                <p>The Toll-like receptor 4 (TLR4) has been implicated in the pathogenesis of various metabolic and
                    cardiovascular diseases, primarily through its role in modulating inflammatory responses. TLR4
                    activation by ligands such as palmitic acid (PA) has been shown to influence cytokine profiles in
                    innate immune cells, contributing to the development of type 2 diabetes [5]. Specifically, PA
                    binding
                    to TLR4/MD-2 complex leads to the secretion of pro-inflammatory cytokines like IL-1β, which is
                    crucial
                    in the progression of diabetes [5]. Additionally, TLR4 signaling pathways, including the
                    MyD88-dependent and TRIF-dependent pathways, play significant roles in the inflammatory processes
                    associated with metabolic disorders [55]. Dysregulated TLR4 signaling is also linked to the
                    pathogenesis of cardiovascular diseases, such as atherosclerosis, where macrophage-expressed
                    adipocyte
                    fatty acid-binding protein accelerates disease progression in hypercholesterolemic conditions
                    [5].</p>
                <p>Therapeutic applications of TLR4 agonists in metabolic and cardiovascular diseases are being actively
                    explored. For instance, the use of TLR4 agonists has shown promise in enhancing host resistance to
                    infections, which could indirectly benefit metabolic health by reducing systemic inflammation [11].
                    In
                    the context of atherosclerosis, targeting TLR4 with specific agonists or antagonists could modulate
                    macrophage function and cytokine production, potentially slowing disease progression [5]. Moreover,
                    the anti-inflammatory properties of certain TLR4 agonists, such as sp2-iminosugar glycolipids, have
                    demonstrated therapeutic potential in reducing inflammation and promoting a balanced immune
                    response,
                    which could be beneficial in managing metabolic and cardiovascular diseases [55].</p>
                <p>Despite promising preclinical data, the efficacy and safety of TLR4 agonists in metabolic and
                    cardiovascular diseases require validation through clinical trials. Current therapies for these
                    conditions often fail to address the underlying inflammatory mechanisms, highlighting the need for
                    novel interventions targeting TLR4 pathways [57]. Clinical trials are essential to determine the
                    therapeutic potential of TLR4 agonists in improving metabolic and cardiovascular health, ensuring
                    that
                    these agents can be safely integrated into treatment regimens. Future research should focus on
                    optimizing the delivery systems and dosing strategies for TLR4 agonists, as well as exploring their
                    long-term effects on metabolic and cardiovascular outcomes [57].</p>
                <h2 id="5-tlr4-agonists-in-neurological-disorders">5. TLR4 Agonists in Neurological Disorders</h2>
                <h3 id="5-1-neurodegenerative-diseases">5.1. Neurodegenerative Diseases</h3>
                <p>The role of TLR4 in neurodegenerative diseases is multifaceted, involving both detrimental and
                    potentially therapeutic effects. Mechanistically, TLR4 activation by damage-associated molecular
                    patterns (DAMPs) and pathology-associated proteins such as amyloid-β (Aβ) and α-synuclein can
                    exacerbate neurodegeneration. These proteins bind to TLR4, triggering downstream signaling pathways
                    in
                    glial cells that lead to the secretion of reactive oxygen species (ROS) and pro-inflammatory
                    cytokines
                    like TNF-α and IL-1β, which contribute to neuronal death [57]. Chronic TLR4 activation is
                    particularly
                    harmful, as it results in excessive cytotoxin secretion and sustained neuroinflammation, further
                    propagating neuronal damage [57]. Additionally, TLR4 activation has been implicated in tau
                    hyperphosphorylation and aggregation, processes that are central to the pathology of Alzheimer&#39;s
                    disease (AD) and Parkinson&#39;s disease (PD) [57]. TLR4 also interacts with NMDA receptors,
                    contributing to excitotoxicity, a condition where excessive glutamate causes neuronal injury and
                    death
                    [57].</p>
                <p>Despite these detrimental effects, TLR4 agonists have shown promise in preclinical models for their
                    potential therapeutic applications. For instance, TLR4 activation can enhance the phagocytosis of
                    neurotoxic proteins like Aβ and α-synuclein, aiding in their clearance from the brain [57]. Chronic
                    stimulation of TLR4 has been demonstrated to reduce tauopathy in transgenic murine models of AD,
                    suggesting that TLR4 agonists could be used to mitigate tau-related neurodegeneration [57].
                    Monophosphoryl lipid A (MPL), a TLR4 agonist, has shown neuroprotective effects in AD models by
                    preventing Aβ accumulation and improving cognitive function [57]. Similarly, E6020, another TLR4
                    agonist, has been shown to promote myelin regeneration and axon sparing in multiple sclerosis (MS)
                    models, indicating its potential for treating demyelinating diseases [22]. Selective activation of
                    the
                    MyD88-independent TLR4 pathway could balance the beneficial effects of phagocytosis with reduced
                    inflammation, offering a targeted therapeutic strategy [57].</p>
                <p>Preclinical evidence supports the potential of TLR4 agonists in treating neurodegenerative diseases.
                    MPL has demonstrated neuroprotective effects in both AD and ischemia models, showing reduced amyloid
                    plaque load and improved cognitive function [57]. E6020 has been effective in promoting
                    remyelination
                    and axon sparing in MS models, with studies showing enhanced myelin debris clearance and increased
                    axon myelination [22]. However, despite these promising results, the clinical development of TLR4
                    agonists has been limited, and further research is needed to establish their safety and efficacy in
                    human patients [57]. Future studies should focus on optimizing TLR4 agonists to maximize their
                    therapeutic benefits while minimizing potential adverse effects, paving the way for new treatments
                    for
                    neurodegenerative diseases.</p>
                <h3 id="5-2-acute-neurological-conditions">5.2. Acute Neurological Conditions</h3>
                <p>Acute neurological conditions such as stroke and traumatic brain injury (TBI) involve complex
                    pathophysiological mechanisms where TLR4 plays a pivotal role. Following ischemia or trauma,
                    damage-associated molecular patterns (DAMPs) are released into the extracellular space, activating
                    TLR4 and initiating a cascade of neuroinflammatory responses. This activation contributes to
                    secondary
                    brain injury through sustained neuroinflammation, excitotoxicity, and neuronal apoptosis [57]. In
                    models of TBI, TLR4 activation has been shown to increase the expression of pro-inflammatory
                    cytokines
                    such as IL-1β and TNF-α, exacerbating neuronal damage [57]. Similarly, in acute cerebral infarction,
                    upregulated TLR4 expression in monocytes correlates with the severity of the infarct, indicating its
                    significant role in the progression of ischemic injury [57].</p>
                <p>The therapeutic potential of modulating TLR4 activity in acute neurological conditions is
                    substantial.
                    TLR4-mediated neuroinflammation impacts neuronal survival, and targeting this pathway could mitigate
                    the detrimental effects of excessive inflammation. TLR4 agonists, such as monophosphoryl lipid A
                    (MPL), have shown promise in enhancing the clearance of cytotoxic debris, potentially aiding in
                    tissue
                    repair and recovery [57]. Conversely, TLR4 antagonists like Eritoran and STM28 have demonstrated
                    efficacy in reducing neuroinflammation and neuronal autophagy, thereby preventing chronic injury
                    post-acute phase [57]. The balance between inflammation and tissue repair is crucial, and modulating
                    TLR4 activity could provide a therapeutic strategy to optimize this balance in acute neurological
                    conditions.</p>
                <p>Despite promising preclinical evidence, clinical trial data on TLR4 agonists and antagonists in acute
                    neurological conditions remain limited. Preclinical studies have shown that TLR4 agonists can reduce
                    infarct size and improve cognitive function in ischemia models, highlighting their potential
                    therapeutic benefits [57]. However, the translation of these findings into clinical practice
                    requires
                    further research to establish the safety and efficacy of TLR4-targeted therapies in human trials.
                    The
                    need for comprehensive clinical studies is evident to validate these preclinical results and to
                    explore the full therapeutic potential of TLR4 modulation in acute neurological conditions.</p>
                <h2 id="6-tlr4-agonists-in-metabolic-and-cardiovascular-diseases">6. TLR4 Agonists in Metabolic and
                    Cardiovascular Diseases</h2>
                <h3 id="6-1-metabolic-disorders">6.1. Metabolic Disorders</h3>
                <p>TLR4 agonists have emerged as significant players in the context of metabolic disorders, particularly
                    obesity and type 2 diabetes. The activation of TLR4 by lipopolysaccharide (LPS) has been shown to
                    affect hypothalamic arcuate nucleus (ARC) neurons, which are crucial for regulating food intake and
                    body weight [23]. Additionally, palmitic acid (PA), a saturated fatty acid, can activate TLR4,
                    leading
                    to the secretion of IL-1β from human dendritic cells (MoDCs). This cytokine is implicated in the
                    development of type 2 diabetes by promoting inflammatory responses [5]. The role of PA in modulating
                    immune cell cytokine profiles and its positive correlation with type 2 diabetes incidence
                    underscores
                    the importance of TLR4 in metabolic inflammation [5]. Furthermore, PA-induced IL-1β supports the
                    development of Th17 cells, which are drivers of inflammation in both type 1 and type 2 diabetes [5].
                    High serum lipid levels, such as those of PA, can also downregulate CD1 molecules in MoDCs,
                    potentially contributing to immunological dysfunction in type 2 diabetes [5].</p>
                <p>The mechanisms by which TLR4 activation influences metabolic inflammation and insulin resistance are
                    multifaceted. TLR4 activation leads to the secretion of inflammatory cytokines like IL-6 and TNF-α,
                    which contribute to metabolic inflammation and insulin resistance [23]. Selective TLR4 agonists
                    could
                    modulate immune responses, potentially reducing inflammation without excessive cytokine production
                    [10]. TLR4-mediated signaling pathways, including MyD88-dependent and TRIF-dependent pathways, play
                    crucial roles in the metabolic reprogramming of macrophages [10]. This reprogramming enhances the
                    ability of macrophages to clear cytotoxic debris and reduce oxidative stress, which are critical
                    factors in metabolic disorders [10]. Targeting TLR4 could thus offer a therapeutic strategy to
                    mitigate the inflammatory and oxidative stress components of metabolic diseases.</p>
                <p>Preclinical evidence supports the therapeutic potential of TLR4 agonists in improving metabolic
                    outcomes. Studies have shown that TLR4 agonists like monophosphoryl lipid A (MPLA) can induce
                    metabolic reprogramming in macrophages, enhancing their ability to clear infections and reduce
                    inflammation [10]. In animal models of obesity and diabetes, MPLA treatment has been associated with
                    improved metabolic outcomes and reduced inflammation [47]. These findings suggest that TLR4 agonists
                    can modulate immune responses in a way that offers therapeutic benefits in metabolic diseases,
                    potentially paving the way for new treatments for conditions like obesity and type 2 diabetes
                    [47].</p>
                <h3 id="6-2-cardiovascular-diseases">6.2. Cardiovascular Diseases</h3>
                <p>TLR4 activation plays a significant role in the pathogenesis of cardiovascular diseases, particularly
                    atherosclerosis and heart failure. In atherosclerosis, TLR4 activation modulates inflammatory
                    responses in macrophages, contributing to the development and progression of the disease [5]. The
                    engagement of TLR4 with its ligands leads to the activation of downstream signaling pathways,
                    including the MyD88-dependent and TRIF-dependent pathways, which result in the production of
                    pro-inflammatory cytokines and chemokines [55]. This inflammatory milieu promotes the recruitment of
                    additional immune cells to the atherosclerotic plaques, exacerbating the inflammatory response and
                    plaque instability. Furthermore, TLR4 signaling has been implicated in the calcification processes
                    observed in calcific aortic valve disease (CAVD). In adult aortic valve interstitial cells (AVICs),
                    TLR4 stimulation activates protein kinases such as p38 MAPK and the transcription factor NF-κB,
                    leading to a pro-inflammatory and pro-osteogenic phenotype characterized by the production of
                    bone-forming proteins and inflammatory cytokines [54].</p>
                <p>The mechanisms by which TLR4 contributes to cardiovascular diseases extend beyond inflammation to
                    include oxidative stress and tissue remodeling. TLR4 signaling in cardiac tissues promotes the
                    production of inflammatory cytokines and reactive oxygen species, which contribute to cardiac
                    hypertrophy and heart failure [55]. Inhibition of TLR4 signaling has been shown to reduce
                    inflammation
                    and calcification in preclinical models of cardiovascular diseases. For instance, TLR4 antagonists
                    like TAK-242 (resatorvid) have demonstrated efficacy in reducing chronic inflammation and protecting
                    against tissue damage in various models [57]. Additionally, TLR4 agonists such as MPLA and E6020
                    have
                    shown potential in promoting myelin regeneration and reducing cardiac inflammation, suggesting a
                    complex role of TLR4 modulation in cardiovascular health [57].</p>
                <p>Clinical trials investigating TLR4-targeted therapies in cardiovascular diseases are still in their
                    early stages. However, preclinical evidence supports the therapeutic potential of modulating TLR4
                    pathways. For example, the TLR4 antagonist Eritoran has shown promise in reducing lethality in
                    influenza-infected mice by decreasing inflammatory cytokine production, highlighting the potential
                    of
                    TLR4 inhibition in managing severe inflammatory responses [50]. While studies specifically targeting
                    TLR4 in cardiovascular diseases are limited, the existing data suggest that TLR4 antagonists could
                    offer benefits in reducing inflammation and improving cardiac outcomes. Further clinical trials are
                    necessary to evaluate the safety and efficacy of TLR4-targeted therapies in cardiovascular diseases,
                    paving the way for novel therapeutic strategies in managing these conditions [57].</p>
                <h2 id="7-tlr4-agonists-in-allergy-and-asthma">7. TLR4 Agonists in Allergy and Asthma</h2>
                <h3 id="7-1-mechanisms-of-action-in-asthma">7.1. Mechanisms of Action in Asthma</h3>
                <p>TLR4 agonists play a crucial role in modulating immune responses in asthma by promoting a shift from
                    Th2 to Th1 polarization, which is beneficial in counteracting Th2-dominated inflammatory pathologies
                    like asthma. Activation of TLR4 leads to the production of IFNγ, a cytokine associated with Th1
                    responses, which can reduce Th2 cytokines such as IL-4 and IL-13 [56]. This shift is essential
                    because
                    Th2 responses are typically associated with allergic inflammation and asthma, characterized by
                    elevated levels of IL-4, IL-5, and IL-13, which contribute to airway hyperresponsiveness and mucus
                    production. By promoting Th1 responses, TLR4 agonists help in reducing these Th2-mediated effects,
                    thereby alleviating asthma symptoms.</p>
                <p>The signaling pathways involved in TLR4 activation are complex and include both MyD88-dependent and
                    TRIF-dependent pathways. The MyD88-dependent pathway is associated with the rapid production of
                    pro-inflammatory cytokines and innate immune responses, while the TRIF-dependent pathway is linked
                    to
                    the production of type I interferons and the maturation of dendritic cells [9]. This dual signaling
                    mechanism allows TLR4 agonists to balance pro-inflammatory and anti-inflammatory responses
                    effectively. For instance, the MyD88 pathway leads to the activation of NF-κB and the production of
                    pro-inflammatory cytokines, which are crucial for immediate immune responses [9]. On the other hand,
                    the TRIF pathway promotes adaptive immune responses, which are essential for long-term immunity and
                    effective vaccination [9]. This balance is particularly important in asthma, where excessive
                    inflammation can exacerbate symptoms, while a controlled immune response can help in managing the
                    disease.</p>
                <p>Moreover, TLR4 agonists enhance the phagocytic activity of immune cells, aiding in the clearance of
                    allergens and reducing airway inflammation. The role of TLR4 in different cell types, including
                    structural airway cells (SACs) and hematopoietic cells (HPCs), suggests a dual mechanism where SACs
                    promote Th2 responses and HPCs promote Th1 responses [33]. This dual role is significant because it
                    highlights the potential of TLR4 agonists to modulate immune responses at multiple levels, thereby
                    providing a comprehensive approach to managing asthma. For example, while SACs may contribute to the
                    local inflammatory environment by promoting Th2 responses, HPCs can counteract this by promoting Th1
                    responses, thereby achieving a balanced immune response that mitigates asthma symptoms.
                    Understanding
                    these mechanisms is crucial for developing effective TLR4-based therapies for asthma and other
                    allergic diseases.</p>
                <h3 id="7-2-therapeutic-potential-and-clinical-evidence">7.2. Therapeutic Potential and Clinical
                    Evidence</h3>
                <p>The therapeutic potential of TLR4 agonists in asthma has been extensively studied, with promising
                    results indicating their ability to reduce airway hyperresponsiveness (AHR) and Th2 cytokine levels.
                    Preclinical models have demonstrated that TLR4 agonists, such as monophosphoryl lipid A (MPLA), can
                    significantly decrease AHR and the expression of Th2 cytokines like IL-4 and IL-13 in
                    bronchoalveolar
                    fluid (BALF) and lung tissues. For instance, in an ovalbumin (OVA)-induced AHR mouse model,
                    compounds
                    related to TLR4 agonists were shown to curtail pulmonary resistance by as much as 50% and reduce
                    IL-4
                    and IL-13 levels in BALF and lung tissues [55]. These findings suggest that TLR4 agonists can
                    effectively mitigate airway inflammation, a key feature of asthma.</p>
                <p>Clinical evidence further supports the use of TLR4 agonists in enhancing the efficacy of
                    allergen-specific immunotherapy (AIT). Studies have shown that TLR4 agonists can promote Th1
                    responses, which are crucial for counteracting the Th2-dominated immune responses typically seen in
                    allergic conditions. For example, the use of MPLA in combination with grass pollen allergens has
                    been
                    shown to boost AIT by inducing IFNγ production and reducing IgE levels in allergic patients [56].
                    Additionally, the conjugation of MPLA to ovalbumin (OVA) protein has been reported to promote
                    dendritic cell (DC) maturation and induce a Th1 response, further enhancing the therapeutic efficacy
                    of AIT [56]. These findings highlight the potential of TLR4 agonists to improve clinical outcomes in
                    allergic patients by modulating immune responses.</p>
                <p>Moreover, TLR4 agonists have shown promise in clinical trials for their ability to modulate immune
                    responses and reduce inflammation in asthma. For instance, the administration of TLR4 agonists has
                    been associated with increased production of IFNγ and decreased levels of Th2 cytokines, such as
                    IL-4
                    and IL-5, in allergic patients [56]. This shift towards a Th1 response is beneficial in reducing the
                    allergic inflammation characteristic of asthma. Additionally, TLR4 agonists have been shown to
                    enhance
                    the efficacy of AIT by promoting a more balanced immune response, thereby improving clinical
                    outcomes
                    in patients with asthma and other allergic conditions [55]. These findings underscore the
                    therapeutic
                    potential of TLR4 agonists in managing asthma and highlight the need for further research to
                    optimize
                    their use in clinical settings.</p>
                <h3 id="7-3-role-in-conditions-like-allergic-rhinitis-and-atopic-dermatitis">7.3. Role in Conditions
                    like
                    Allergic Rhinitis and Atopic Dermatitis</h3>
                <p>TLR4 agonists have demonstrated significant potential in modulating immune responses in allergic
                    conditions such as allergic rhinitis and atopic dermatitis. These agonists can promote Th1
                    responses,
                    which are crucial for counterbalancing the Th2-dominated immune responses typically observed in
                    allergic diseases. The activation of TLR4 on hematopoietic cells (HPCs) can trigger signaling
                    pathways
                    that program dendritic cells (DCs) to polarize the immune response toward Th1 states, thereby
                    attenuating allergen-triggered Th2 sensitization and providing protection from airway
                    hyperreactivity
                    (AHR) [55]. This shift from a Th2 to a Th1 response is essential for reducing the clinical symptoms
                    associated with allergic rhinitis and atopic dermatitis.</p>
                <p>The ability of TLR4 agonists to reduce Th2 cytokines and enhance IFN-γ production further underscores
                    their utility in treating various allergic conditions. For instance, TLR4 activation can induce the
                    release of both Th1 cytokines, such as IFN-γ, and Th2 cytokines, like IL-4 and IL-13, in a
                    context-dependent manner [55]. This dual role of TLR4 in different cell types may provide a
                    mechanism
                    for its effectiveness in various allergic conditions. Moreover, studies have shown that TLR4
                    agonists
                    can improve clinical symptoms in allergic rhinitis and atopic dermatitis by modulating immune
                    responses, thereby reducing inflammation and promoting a more balanced immune profile [56].</p>
                <p>Furthermore, TLR4 agonists can enhance the efficacy of allergen-specific immunotherapy in conditions
                    like allergic rhinitis by promoting Th1 responses. The co-delivery of TLR4 and TLR7/8 agonists has
                    been reported to result in synergistic immune responses, driving increased cytokine production and
                    Th1-Th2 balanced responses both in vitro and in vivo [33]. This synergy can be leveraged to enhance
                    the immunogenic characteristics of allergen-specific immunotherapy, making it more effective in
                    treating allergic conditions. By promoting a regulatory pattern with IFN-γ and IL-10 production,
                    TLR4
                    agonists can help suppress Th2 effector cells and support the induction of Treg cells, thereby
                    improving the overall outcome of allergen immunotherapy [56].</p>
                <h3 id="7-4-clinical-trial-data-and-outcomes">7.4. Clinical Trial Data and Outcomes</h3>
                <p>Clinical trials have demonstrated the efficacy of TLR4 agonists in reducing symptoms and improving
                    clinical outcomes in allergic conditions such as allergic rhinitis and atopic dermatitis. For
                    instance, allergen-specific immunotherapy (AIT) using TLR4 agonists has shown promising results in
                    managing grass-pollen-induced allergic rhinoconjunctivitis. These treatments have been effective in
                    modulating the immune response, shifting it from a Th2-dominated profile to a more balanced Th1/Th2
                    response, which is crucial for reducing allergic symptoms [56]. Additionally, the use of TLR4
                    agonists
                    in combination with other immunomodulatory agents, such as CpG oligodeoxynucleotides, has been shown
                    to enhance the efficacy of AIT by promoting Th1 responses and reducing IgE levels, further
                    supporting
                    their potential in treating allergic conditions [56].</p>
                <p>The safety profiles of TLR4 agonists in clinical trials have been favorable, with no significant new
                    safety concerns reported. For example, the use of monophosphoryl lipid A (MPL), a TLR4 agonist, as
                    an
                    adjuvant in vaccines has been well-tolerated in various studies, including those targeting allergic
                    diseases [57]. Moreover, the combination of TLR4 agonists with other therapeutic agents has not
                    resulted in any unexpected adverse effects, indicating their potential for safe use in clinical
                    settings. However, it is important to note that while short-term safety data are encouraging,
                    long-term follow-up studies are needed to assess the sustained efficacy and safety of TLR4 agonists
                    in
                    treating allergic conditions [57].</p>
                <p>Overall, clinical trial data support the potential of TLR4 agonists as a therapeutic option for
                    various
                    allergic conditions. These trials have highlighted their ability to enhance allergen-specific
                    immunotherapy, reduce allergic symptoms, and maintain a favorable safety profile. Ongoing research
                    aims to optimize the use of TLR4 agonists, including the development of novel formulations and
                    delivery systems to improve their efficacy and patient compliance [56][57]. As the field progresses,
                    it will be crucial to continue monitoring the long-term outcomes of these treatments to fully
                    understand their potential and limitations in managing allergic diseases.</p>
                <h2 id="8-future-directions">8. Future Directions</h2>
                <h3 id="1-safety-and-efficacy-of-tlr4-agonists">8.1. Safety and Efficacy of TLR4 Agonists</h3>
                <p>The general safety profile of TLR4 agonists has been extensively studied in various preclinical and
                    clinical settings. For instance, E6020, a synthetic lipid A mimetic, has shown a favorable safety
                    profile in multiple animal models. In studies involving rats, subcutaneous administration of E6020
                    at
                    5 mg/kg/day for two weeks resulted in no observable adverse effects other than transient increases
                    in
                    spleen weight and white blood cell counts, which normalized within 24 hours [57]. Similarly, in
                    cynomolgus monkeys, subcutaneous injections of E6020 at doses up to 1 mg/kg caused only localized
                    swelling and redness, with systemic effects such as increased blood pressure and heart rate
                    diminishing within 24 hours [57]. These findings suggest that TLR4 agonists like E6020 can be
                    administered safely at therapeutic doses, although localized and transient systemic reactions may
                    occur.</p>
                <p>Adverse effects associated with TLR4 agonists are generally manageable and often transient. For
                    example, TAK-242 (Resatorvid), a small molecule TLR4 antagonist, has been shown to reduce symptoms
                    of
                    chronic pancreatitis in rats without significant adverse effects [57]. However, some TLR4 agonists
                    can
                    induce robust immune responses, which may lead to inflammatory side effects. E6020 analogs, for
                    instance, have been reported to cause significant cytokine secretion, including IL-1α, IL-1β, IL-6,
                    and TNF-α, in human peripheral blood mononuclear cells [57]. Management strategies for these adverse
                    effects typically involve dose adjustments and monitoring of inflammatory markers to mitigate
                    potential risks. Long-term studies are essential to fully understand the chronic safety profile of
                    these agents, especially in the context of autoimmune and inflammatory diseases where prolonged
                    treatment may be necessary.</p>
                <p>Long-term efficacy and monitoring are crucial for the sustained therapeutic benefits of TLR4
                    agonists.
                    Clinical trials and extended preclinical studies are necessary to ensure that these agents provide
                    lasting benefits without causing cumulative toxicity or adverse effects. For instance, the use of
                    TLR4
                    agonists in treating autoimmune diseases like type 1 diabetes (T1D) has shown promise in preserving
                    β-cell function through immune tolerance induction [34]. However, continuous monitoring of patients
                    for potential long-term adverse effects, such as chronic inflammation or immune dysregulation, is
                    imperative. The need for further research to confirm the safety and efficacy of TLR4 agonists in
                    clinical applications cannot be overstated, as it will help refine therapeutic protocols and improve
                    patient outcomes in the management of autoimmune and inflammatory diseases.</p>
                <h3 id="8-2-discovery-and-development-of-novel-tlr4-agonists">8.2. Discovery and Development of Novel
                    TLR4
                    Agonists</h3>
                <p>The discovery and development of novel TLR4 agonists have been significantly advanced by the use of
                    high-throughput screening (HTS) and Förster resonance energy transfer (FRET) assays. These
                    techniques
                    enable the rapid identification of new chemotypes that can bind and activate TLR4. For instance, a
                    series of pyrimido[5,4-b]indoles were identified as selective TLR4 agonists through HTS, revealing
                    the
                    benzyl ring as a key site for structural modification without altering binding properties [56].
                    Additionally, the development of 4-substituted aminoquinazolines has shown promise as MD-2 dependent
                    and CD14 independent TLR4 agonists, further expanding the repertoire of small molecules capable of
                    modulating TLR4 activity [57].</p>
                <p>Synthetic small molecules offer several advantages in the development of TLR4 agonists, including
                    structural optimization, scalability, and stability. Notable examples include neoseptins and
                    euodenine
                    A, which act as non-LPS-like small molecules that activate TLR4. Euodenine A, for instance, has been
                    shown to bind TLR4/MD-2 independently of CD14 and induce cytokine secretion in human PBMCs,
                    demonstrating its potential as a novel TLR4 agonist [57]. The structural rigidity and specific
                    acylation and phosphorylation patterns of synthetic glycolipids, such as disaccharide-based lipid A
                    mimetics (DLAMs), ensure high affinity for TLR4 and efficient dimerization of TLR4/MD-2 complexes,
                    highlighting the potential of synthetic approaches in TLR4 agonist development [7].</p>
                <p>FTIR spectroscopy, supported by artificial intelligence (AI) and multivariate analysis, has emerged
                    as
                    a valuable tool for gaining preliminary mechanistic insights during drug screening. This technique
                    provides a comprehensive molecular fingerprint of intact cells, allowing for the identification of
                    key
                    biomolecular changes in response to TLR4 agonists. For example, the spectroscopic fingerprint of
                    cells
                    treated with rationally designed TLR4 agonists, such as FP20 and FP20Rha, revealed specific IR bands
                    associated with lipids and glycans, which were involved in the cellular response to these agonists
                    [36]. The integration of FTIR spectroscopy with advanced data analysis techniques offers a powerful
                    approach for the discovery and development of novel TLR4 agonists, facilitating the identification
                    of
                    promising candidates with optimized efficacy and safety profiles.</p>
                <h3 id="8-3-advances-in-delivery-systems">8.3. Advances in Delivery Systems</h3>
                <p>Recent advances in delivery systems for TLR4 agonists have significantly enhanced the stability and
                    immunogenicity of antigens, particularly in the context of particulate vaccine delivery systems.
                    These
                    systems, such as polymeric hybrid micelles, lipid core peptides, and chitosan nanoparticles, have
                    been
                    tailored to improve immune responses by facilitating efficient antigen delivery and uptake by
                    antigen-presenting cells (APCs) [39]. One notable innovation is the use of inulin acetate (InAc), a
                    plant polymeric TLR4 agonist, which has shown promise in particulate vaccine delivery systems.
                    InAc-based nanoparticles (InAc-NPs) have demonstrated superior antigen delivery capabilities
                    compared
                    to traditional materials like PLGA, owing to their ability to interact intimately with nasal mucosa
                    and enhance antigen uptake by APCs [39].</p>
                <p>InAc-NPs have been specifically developed for mucosal vaccination through intranasal delivery, a
                    method
                    that offers several advantages, including ease of administration and the induction of both systemic
                    and mucosal immunity [39]. The preparation of InAc-NPs involves acetylating the hydroxyl functional
                    groups of inulin, resulting in nanoparticles with an average diameter of around 245 nm and a neutral
                    to slightly negative charge, which are efficiently recognized and internalized by APCs [39]. These
                    nanoparticles have been shown to produce strong humoral and systemic immune responses, including
                    mucosal immunity, against encapsulated antigens when administered intranasally, thereby providing
                    complete cross-protection against lethal virus attacks [39]. This makes InAc-NPs a versatile and
                    potent nasal vaccine adjuvant/delivery system.</p>
                <p>However, challenges remain in encapsulating proteins into hydrophobic polymeric matrices and
                    achieving
                    sustained antigen release. The high hydrophobicity of InAc, while beneficial for TLR4 activation,
                    can
                    complicate the encapsulation process and affect the release kinetics of the antigen [39]. Despite
                    these challenges, InAc-NPs have demonstrated higher antigen delivery capability and stronger
                    cytokine
                    release compared to PLGA particles, emphasizing the potential role of InAc-TLR4 interaction in
                    particle/vaccine recognition [39]. Continued research and innovation in this field are essential to
                    overcome these challenges and further enhance the efficacy of TLR4 agonist-based vaccines, paving
                    the
                    way for more effective prevention and treatment of infectious diseases.</p>
                <h3 id="8-4-emerging-technologies-and-methodologies">8.4. Emerging Technologies and Methodologies</h3>
                <p>The landscape of TLR4 agonist research is rapidly evolving with the integration of advanced
                    technologies and innovative methodologies. One of the most promising advancements is the application
                    of machine learning (ML) and artificial intelligence (AI) to evaluate molecular signatures and
                    similarities between different TLR4 agonists. These computational tools can analyze vast datasets to
                    identify patterns and predict the biological activity of new compounds, significantly accelerating
                    the
                    drug discovery process. For instance, FTIR spectroscopy, supported by AI and multivariate analysis,
                    has been proposed to achieve a holistic understanding of cell responses to new drug candidates,
                    providing preliminary mechanistic insights in a faster and more cost-effective manner compared to
                    traditional methods [36]. This approach not only enhances the efficiency of screening but also
                    offers
                    a more comprehensive view of the molecular interactions at play.</p>
                <p>Computational approaches are also being leveraged to identify potential TLR4 agonists and optimize
                    their synthesis and production. High-throughput screening of large compound libraries has already
                    led
                    to the discovery of novel TLR4 agonists, such as neoseptins, which activate the murine MD2
                    coreceptor
                    [12]. Additionally, structure-activity relationship (SAR) studies have been instrumental in refining
                    the chemical structures of lead compounds to improve their potency and reduce toxicity. For example,
                    modifications to the pyrimido[5,4-b]indole scaffold have yielded derivatives with significantly
                    enhanced TLR4 agonist activity, particularly those with aryl groups at the C8 position [38]. These
                    computational strategies not only streamline the identification of promising candidates but also
                    facilitate the rational design of more effective and safer TLR4 agonists.</p>
                <p>Another innovative approach in TLR4 agonist research involves the development of smart liposomal
                    nanocarriers. These nanocarriers can be engineered to target specific pathways, thereby improving
                    the
                    delivery and therapeutic outcomes of TLR4 agonists. For instance, co-encapsulation of TLR4 and
                    TLR7/8
                    agonists in liposomes has been shown to produce uniform particles with enhanced stability and
                    efficacy
                    [33]. Additionally, the use of pharmacological chaperones to stabilize misfolded enzymes and enhance
                    their activity represents a novel strategy to improve the functionality of TLR4 agonists. The
                    integration of high-throughput technologies for IR spectra collection and analysis further
                    complements
                    these efforts, enabling rapid and detailed characterization of drug candidates [36]. Together, these
                    emerging technologies and methodologies hold great promise for advancing the development of TLR4
                    agonists and their application in various therapeutic contexts.</p>
                <h3 id="8-5-challenges-and-solutions-in-tlr4-agonist-development">8.5. Challenges and Solutions in TLR4
                    Agonist Development</h3>
                <p>The development of TLR4 agonists faces several significant challenges, primarily due to stringent
                    regulatory requirements and the need for extensive safety and efficacy data. Regulatory bodies
                    demand
                    comprehensive evidence to ensure that new TLR4 agonists are both safe and effective before they can
                    be
                    approved for clinical use. This necessitates rigorous preclinical and clinical testing to
                    demonstrate
                    the specificity and mechanism of action of these agonists, which can be particularly challenging
                    given
                    the structural diversity and promiscuity of TLR4 ligands [21]. Additionally, the development of
                    combination therapies involving TLR4 agonists introduces further regulatory complexities, as it
                    requires demonstrating the safety and efficacy of each component as well as their combined effects
                    [33].</p>
                <p>To address these challenges, researchers have employed various strategies to ensure the specificity
                    and
                    purity of TLR4 agonists. One approach involves the use of synthetic routes to prepare TLR4 agonists,
                    thereby eliminating concerns about contamination with other agonists [21]. This is crucial for
                    accurately attributing observed biological effects to the intended TLR4 agonist. Furthermore, the
                    implementation of co-culture systems to produce candidate protein agonists in situ can help in
                    validating the direct activation of TLR4, as it allows for the controlled study of interactions
                    within
                    a biologically relevant environment [21]. These methods, combined with advanced computational
                    techniques for predicting and validating TLR4-binding peptides, have shown promise in identifying
                    novel agonists with high specificity and reduced production costs [12].</p>
                <p>Another critical aspect of overcoming challenges in TLR4 agonist development is the optimization of
                    dosing strategies and combination treatments to enhance therapeutic efficacy. Co-encapsulation of
                    TLR4
                    agonists with other immune-stimulating agents, such as TLR7/8 ligands, within liposomal formulations
                    has demonstrated synergistic effects on both innate and adaptive immune responses [33]. This
                    approach
                    not only improves the immunogenicity of vaccines but also allows for dose sparing, which is
                    particularly beneficial in clinical settings. Additionally, the identification of novel interactions
                    with TLR4 and/or MD-2, as seen with various synthetic and natural peptides, provides a pathway for
                    developing more effective and targeted TLR4 agonists [12]. By addressing these challenges through
                    innovative solutions, the development of TLR4 agonists can be significantly advanced, paving the way
                    for new therapeutic applications in infectious, autoimmune, and inflammatory diseases.</p>
                <h3 id="8-6-new-therapeutic-applications-and-personalized-medicine">8.6. New Therapeutic Applications
                    and
                    Personalized Medicine</h3>
                <p>The exploration of TLR4 agonists for the treatment of neurodegenerative diseases, cancer, and
                    infectious diseases represents a promising frontier in medical research. TLR4 agonists have shown
                    potential in enhancing host resistance to infections and treating sepsis by reprogramming immune
                    cells
                    to respond more effectively to pathogens [10]. Additionally, the unique ability of certain TLR4
                    agonists to modulate peripheral immune cell activity specifically through TLR4 activation suggests
                    their potential use in neuroinflammatory disorders and other CNS-related conditions [57]. In cancer
                    therapy, TLR4 agonists could serve as immune system enhancers, complementing existing
                    immunotherapeutic approaches and acting as new vaccine adjuvants for both infectious diseases and
                    oncology [37]. The development of innovative TLR4 activators, such as cyclic and linear peptides
                    targeting MD2 and CD14, further underscores the potential of these molecules in various therapeutic
                    settings [12].</p>
                <p>The development of TLR4 agonists as vaccine adjuvants to enhance immune responses is another
                    significant area of interest. TLR4-based ligands, such as monophosphoryl lipid A, have already been
                    incorporated into licensed vaccines like Cervarix, demonstrating their safety and efficacy [38]. The
                    co-delivery of TLR4 and TLR7/8 agonists has been shown to enhance Th1 responses and provide broad
                    protection when administered as a vaccine, highlighting the potential for synergistic effects when
                    combining different TLR agonists [33]. Furthermore, the combination of TLR4 agonists with
                    antibiotics
                    has been investigated to enhance bacterial clearance, particularly in conditions where inflammation
                    induces damage to the intestinal epithelium, making it more permeable to bacteria [20]. This
                    approach
                    could be particularly beneficial in treating nosocomial and viral infections, where enhanced immune
                    responses are crucial for effective pathogen clearance.</p>
                <p>Personalized medicine approaches hold great promise for optimizing TLR4 agonist therapies. Tailoring
                    treatments based on individual patient profiles and disease characteristics can help maximize
                    therapeutic efficacy while minimizing adverse effects. The use of biomarkers to identify patients
                    who
                    are likely to respond to TLR4 agonist treatments is a critical step in this direction [57].
                    Additionally, the development of personalized dosing regimens can further enhance treatment outcomes
                    by ensuring that patients receive the most appropriate dose for their specific condition. Advances
                    in
                    delivery systems and emerging technologies will play a crucial role in the successful implementation
                    of personalized TLR4 agonist therapies, paving the way for new therapeutic applications and improved
                    patient care [38].</p>
                <h2 id="9-conclusion">9. Conclusion</h2>
                <p>TLR4 agonists play a crucial role in enhancing immune responses and bolstering resistance to
                    infections. They significantly improve vaccine efficacy, with molecules like monophosphoryl lipid A
                    (MPLA) inducing robust and durable immune responses. These agonists activate the TLR4 signaling
                    pathway, essential for pathogen recognition and innate immunity activation. Combining TLR4 agonists
                    with other TLR ligands enhances both innate and adaptive immune responses.</p>
                <p>Innovative techniques like Fourier-transform infrared (FTIR) spectroscopy, combined with artificial
                    intelligence (AI), offer novel methods for drug screening and understanding the mechanisms of TLR4
                    agonists. This accelerates the discovery of new, more effective, and less toxic TLR4-activating
                    molecules.</p>
                <p>The therapeutic potential of TLR4 agonists extends beyond infectious diseases to cancer,
                    neurodegenerative diseases, and autoimmune disorders. They can reprogram immune cells and modulate
                    inflammatory mediator secretion. However, the dual nature of TLR4 activation necessitates selective
                    modulation to maximize benefits and minimize adverse effects.</p>
                <p>Future research should focus on clinical trials to validate the therapeutic potential of TLR4
                    agonists
                    in various diseases, such as Alzheimer&#39;s and multiple sclerosis. Understanding TLR4-mediated
                    immune responses, particularly the complex signaling pathways, is crucial for developing effective
                    therapies. This includes exploring the MyD88-independent pathways for neuroprotection and optimizing
                    TLR4 agonists as vaccine adjuvants and treatments for neurodegenerative diseases.</p>
                <p>TLR4 agonists hold significant therapeutic promise across infectious, autoimmune, and
                    neurodegenerative
                    diseases. Their ability to enhance immune responses, serve as vaccine adjuvants, and modulate immune
                    functions underscores their importance in modern medicine. However, developing new TLR4 agonists and
                    optimizing them for clinical use is essential, addressing challenges related to toxicity, efficacy,
                    and manufacturing costs.</p>
                <p>Balancing the beneficial and detrimental effects of TLR4 activation is crucial for therapeutic
                    applications. Selective TLR4 agonists targeting specific signaling pathways could mitigate adverse
                    effects while preserving benefits. Advanced technologies like AI and high-throughput screening can
                    accelerate the discovery of effective TLR4 agonists. Collaboration between researchers, clinicians,
                    and pharmaceutical companies is vital for translating research into clinical practice, improving
                    patient outcomes across a range of diseases.</p>
                <h2 id="bibliography">Bibliography</h2>
                <p>[1] Selective serotonin reuptake inhibitor attenuates the hyperresponsivenss of TLR2+ and TLR4+
                    Th17/Tc17-like cells in multiple sclerosis patients with major depression, Immunology, Marisa C.
                    Sales
                    et Al, <a href="https://doi.org/10.1111/imm.13281">10.1111/imm.13281</a></p>
                <p>[2] A metabolite of endophytic fungus Cadophora orchidicola from Kalimeris indica serves as a
                    potential
                    fungicide and TLR4 agonist, Journal of Applied Microbiology (126, 1383-1390), 02-2019, L. Wang et
                    Al, <a href="https://doi.org/10.1111/jam.14239">10.1111/jam.14239</a></p>
                <p>[3] Brain Innate Immunity Regulates Hypothalamic Arcuate Neuronal Activity and Feeding Behavior,
                    Endocrinology, 01-2015, Wagner L. Reis et al, <a
                        href="https://doi.org/10.1210/en.2014-1849">10.1210/en.2014-1849</a></p>
                <p>[4] Toll like Receptor 3 &amp; 4 Responses of Human Turbinate Derived Mesenchymal Stem Cells:
                    Stimulation by Double Stranded RNA and Lipopolysaccharide, PLoS ONE (9(7)), 07-2014, Se Hwan Hwang
                    et
                    al, <a href="https://doi.org/10.1371/journal.pone.0101558">10.1371/journal.pone.0101558</a></p>
                <p>[5] Palmitic acid is a toll-like receptor 4 ligand that induces human dendritic cell secretion of
                    IL-1β, PLOS ONE (12(5)), 05-2017, Dequina A. Nicholas et al., <a
                        href="https://doi.org/10.1371/journal.pone.0176793">10.1371/journal.pone.0176793</a></p>
                <p>[6] Ulvan Activates Chicken Heterophils and Monocytes Through Toll-Like Receptor 2 and Toll-Like
                    Receptor 4, Frontiers in Immunology (Volume 9, Article 2725), 11-2018, Nathalie Guriec et Al, <a
                        href="https://doi.org/10.3389/fimmu.2018.02725">10.3389/fimmu.2018.02725</a></p>
                <p>[7] Tailored Modulation of Cellular Pro-inflammatory Responses With Disaccharide Lipid A Mimetics,
                    Frontiers in Immunology (Volume 12, Article 631797), 03-2021, Holger Heine et Al, <a
                        href="https://doi.org/10.3389/fimmu.2021.631797">10.3389/fimmu.2021.631797</a></p>
                <p>[8] Innate immune responses after stimulation with Toll-like receptor agonists in ex vivo microglial
                    cultures and an in vivo model using mice with reduced microglia, Journal of Neuroinflammation
                    (18:194), 2021, James A. Carroll et Al, <a
                        href="https://doi.org/10.1186/s12974-021-02240-w">10.1186/s12974-021-02240-w</a></p>
                <p>[9] Surface immunogenic protein from Streptococcus agalactiae and Fissurella latimarginata hemocyanin
                    are TLR4 ligands and activate MyD88- and TRIF-dependent signaling pathways, Frontiers in Immunology
                    (14), 09-2023, Diego A. Díaz-Dinamarca et al., <a
                        href="https://doi.org/10.3389/fimmu.2023.1186188">10.3389/fimmu.2023.1186188</a></p>
                <p>[10] MyD88-dependent signaling drives toll-like receptor-induced trained immunity in macrophages,
                    Frontiers in Immunology (Volume 13, Issue 1044662), 11-2022, Allison M. Owen, et Al, <a
                        href="https://doi.org/10.3389/fimmu.2022.1044662">10.3389/fimmu.2022.1044662</a></p>
                <p>[11] The TLR4 Agonist Monophosphoryl Lipid A Drives Broad Resistance to Infection via Dynamic
                    Reprogramming of Macrophage Metabolism, The Journal of Immunology (200: 000–000), 04-2018, Benjamin
                    A.
                    Fensterheim et Al, <a href="https://doi.org/10.4049/jimmunol.1800085">10.4049/jimmunol.1800085</a>
                </p>
                <p>[12] Computationally Designed Bispecific MD2/CD14 Binding Peptides Show TLR4 Agonist Activity, The
                    Journal of Immunology (201, 11), 10-2018, Amit Michaeli et Al, <a
                        href="https://doi.org/10.4049/jimmunol.1800380">10.4049/jimmunol.1800380</a></p>
                <p>[13] Monophosphoryl lipid A alleviated radiation-induced testicular injury through TLR4-dependent
                    exosomes, Journal of Cellular and Molecular Medicine (00), 2020, Zhe Liu et Al, <a
                        href="https://doi.org/10.1111/jcmm.14978">10.1111/jcmm.14978</a></p>
                <p>[14] Mechanism of TLR4-Mediated Anti-Inflammatory Response Induced by Exopolysaccharide from the
                    Probiotic Bacillus subtilis, The Journal of Immunology (211 &amp; 8), 09-2023, Jesus Zamora-Pineda
                    et
                    Al, <a href="https://doi.org/10.4049/jimmunol.2200855">10.4049/jimmunol.2200855</a></p>
                <p>[15] Complete Structure Determination and Chemical Synthesis of Its Lipid A, Angewandte Chemie
                    International Edition (60, 10023-10031), 2021, Atsushi Shimoyama et Al, <a
                        href="https://doi.org/10.1002/anie.202012374">10.1002/anie.202012374</a></p>
                <p>[16] Suppression of Toll-Like Receptor 4 Dimerization by
                    1-[5-Methoxy-2-(2-nitrovinyl)phenyl]pyrrolidine, Archiv der Pharmazie (349, 1–6), 2016, Sang-Il Ahn
                    et
                    Al, <a href="https://doi.org/10.1002/ardp.201600159">10.1002/ardp.201600159</a></p>
                <p>[17] ALight-Controlled TLR4 Agonist and Selectable Activation of Cell Subpopulations, ChemBioChem
                    (16),
                    2015, Lalisa Stutts et Al, <a
                        href="https://doi.org/10.1002/cbic.201500164">10.1002/cbic.201500164</a>
                </p>
                <p>[20] Co-administration of Antimicrobial Peptides (AMPs) Enhances Toll-like Receptor 4 (TLR4)
                    Antagonist
                    Activity of a Synthetic Glycolipid, ChemMedChem, Francesco Peri et Al, <a
                        href="https://doi.org/10.1002/cmdc.201700694">10.1002/cmdc.201700694</a></p>
                <p>[21] Postulates for validating TLR4 agonists, null (null), 12-2014, Mateja Manček-Keber et Al, <a
                    href="https://doi.org/10.1002/eji.201444462">10.1002/eji.201444462</a></p>
                <p>[22] E6020, a synthetic TLR4 agonist, accelerates myelin debris clearance, Schwann cell infiltration,
                    and remyelination in the rat spinal cord, Glia (00), 00-2017, Jamie S. Church et al, <a
                        href="https://doi.org/10.1002/glia.23132">10.1002/glia.23132</a></p>
                <p>[23] A presumed antagonistic LPS identifies distinct functional organization of TLR4 in mouse
                    microglia, Glia (Volume 65, Issue 1), 01-2017, Christin Döring et al., <a
                        href="https://doi.org/10.1002/glia.23151">10.1002/glia.23151</a></p>
                <p>[24] TLR4 agonist protects against Trypanosoma cruzi acute lethal infection by decreasing cardiac
                    parasite burdens., null (null), null, Villanueva-Lizama L.E et al., <a
                        href="https://doi.org/10.1111/pim.12769">10.1111/pim.12769</a></p>
                <p>[25] Saturation of acyl chains converts cardiolipin from an antagonist to an activator of Toll-like
                    receptor-4, Cellular and Molecular Life Sciences, 04-2019, Malvina Pizzuto et Al, <a
                        href="https://doi.org/10.1007/s00018-019-03113-5">10.1007/s00018-019-03113-5</a></p>
                <p>[26] Prestimulation of Microglia Through TLR4 Pathway Promotes Interferon Beta Expression in a Rat
                    Model of Alzheimer’s Disease, Journal of Molecular Neuroscience, 01-2019, Niloufar Yousefi et
                    al., <a
                        href="https://doi.org/10.1007/s12031-018-1249-1">10.1007/s12031-018-1249-1</a></p>
                <p>[27] Lipidomic analysis of local inflammation models shows a specific systemic acute phase response
                    to
                    lipopolysaccharides, BBA - Molecular and Cell Biology of Lipids, 09-2020, Lisa Hahnefeld et Al, <a
                        href="https://doi.org/10.1016/j.bbalip.2020.158822">10.1016/j.bbalip.2020.158822</a></p>
                <p>[28] TLR mediated GSK3 bactivation suppresses CREB mediated IL-10 production to induce a protective
                    immune response against murine visceral leishmaniasis, Biochimie (Volume xxx), 09-2014, Joydeep Paul
                    et Al, <a href="https://doi.org/10.1016/j.biochi.2014.09.004">10.1016/j.biochi.2014.09.004</a></p>
                <p>[29] Antiviral efficacy of orally delivered neoagarohexaose, a nonconventional TLR4 agonist, against
                    norovirus infection in mice, Biomaterials (263), 09-2020, Minwoo Kim et. Al, <a
                        href="https://doi.org/10.1016/j.biomaterials.2020.120391">10.1016/j.biomaterials.2020.120391</a>
                </p>
                <p>[30] Initial optimization and series evolution of diaminopyrimidine inhibitors of interleukin-1
                    receptor associated kinase 4, Bioorganic &amp; Medicinal Chemistry Letters (25), 06-2015, W. Michael
                    Seganish et Al, <a
                        href="https://doi.org/http://dx.doi.org/10.1016/j.bmcl.2015.05.097">http://dx.doi.org/10.1016/j.bmcl.2015.05.097</a>
                </p>
                <p>[31] 17β-Estradiol inﬂuences in vitro response of aged rat splenic conventional dendritic cells to
                    TLR4
                    and TLR7/8 agonists in an agonist specific manner, International Immunopharmacology (Volume 24),
                    11-2014, Zorica Stojić-Vukanić et al, <a
                        href="https://doi.org/10.1016/j.intimp.2014.11.008">10.1016/j.intimp.2014.11.008</a></p>
                <p>[32] Toll-like receptor 4, Toll-like receptor 7 and Toll-like receptor 9 agonists enhance immune
                    responses against blood-stage Plasmodium chabaudi infection in BALB/c mice, International
                    Immunopharmacology (89), 09-2020, Wenyan Gao et Al, <a
                        href="https://doi.org/10.1016/j.intimp.2020.107096">10.1016/j.intimp.2020.107096</a></p>
                <p>[33] Co-encapsulation of synthetic lipidated TLR4 and TLR7/8 agonists in the liposomal bilayer
                    results
                    in a rapid, synergistic enhancement of vaccine-mediated humoral immunity, Journal of Controlled
                    Release, 10-2019, Kristopher K. Short et Al, <a
                        href="https://doi.org/10.1016/j.jconrel.2019.10.025">10.1016/j.jconrel.2019.10.025</a></p>
                <p>[34] Multiple mechanisms involved in diabetes protection by lipopolysaccharide in non-obese diabetic
                    mice, Toxicology and Applied Pharmacology (285 &amp; 2015), 04-2015, Jun Wang et <a
                        href="https://doi.org/al.">al.</a></p>
                <p>[35] Human esophageal myofibroblasts secrete proinflammatory cytokines in response to acid and
                    Toll-like receptor 4 ligands, American Journal of Physiology-Gastrointestinal and Liver Physiology
                    (308: G904–G923), 04-2015, Matthew Gargus et al, <a
                        href="https://doi.org/10.1152/ajpgi.00333.2014">10.1152/ajpgi.00333.2014</a></p>
                <p>[36] Vibrational spectroscopy coupled with machine learning sheds light on the cellular effects
                    induced
                    by rationally designed TLR4 agonists, Talanta (275 &amp; 2024), 04-2024, Diletta Ami et Al, <a
                        href="https://doi.org/10.1016/j.talanta.2024.126104">10.1016/j.talanta.2024.126104</a></p>
                <p>[37] Discovery and Structure–Activity Relationships of the Neoseptins: A New Class of Toll-like
                    Receptor-4 (TLR4) Agonists, Journal of Medicinal Chemistry, 04-2016, Matthew D. Morin et al., <a
                        href="https://doi.org/10.1021/acs.jmedchem.6b00177">10.1021/acs.jmedchem.6b00177</a></p>
                <p>[38] Structure −Activity Relationship Studies of Pyrimido[5,4-b]indoles as Selective Toll-Like
                    Receptor
                    4 Ligands, Journal of Medicinal Chemistry (Volume 60, Issue 21), 10-2017, Michael Chan et Al, <a
                        href="https://doi.org/10.1021/acs.jmedchem.7b00797">10.1021/acs.jmedchem.7b00797</a></p>
                <p>[39] Toll-like Receptor-4 (TLR4) Agonist-Based Intranasal Nanovaccine Delivery System for Inducing
                    Systemic and Mucosal Immunity, Molecular Pharmaceutics (Volume 18, Issue 6), 05-2021, Mohammed Ali
                    Bakkari et Al, <a
                        href="https://doi.org/10.1021/acs.molpharmaceut.0c01256">10.1021/acs.molpharmaceut.0c01256</a>
                </p>
                <p>[40] Prophylactic efficacy of orally administered Bacillus poly-γ-glutamic acid, a non-LPS TLR4
                    ligand,
                    against norovirus infection in mice, Scientific Reports (8:8667), xx-xxxx, Wooseong Lee et Al, <a
                        href="https://doi.org/10.1038/s41598-018-26935-y">10.1038/s41598-018-26935-y</a></p>
                <p>[41] Fungal polysaccharides from Inonotus obliquus are agonists for Toll-like receptors and induce
                    macrophage anti-cancer activity, Communications Biology (7:222), 2024, Christian Winther Wold et
                    Al, <a href="https://doi.org/10.1038/s42003-024-05853-y">10.1038/s42003-024-05853-y</a></p>
                <p>[42] Cellular uptake of exogenous calcineurin B is dependent on TLR4/MD2/CD14 complexes, and CnB is
                    an
                    endogenous ligand of TLR4, Scientific Reports (6:24346), 04-2016, Jinju Yang et Al, <a
                        href="https://doi.org/10.1038/srep24346">10.1038/srep24346</a></p>
                <p>[43] Differential regulation of TLR4 induced IL-10 production in B cells and macrophages reveals a
                    novel role for RSK1 and 2 in B cells, Journal of Biological Chemistry, 12-2017, Ruhcha V. Sutavani
                    et
                    Al, <a href="https://doi.org/10.1074/jbc.M117.805424">10.1074/jbc.M117.805424</a></p>
                <p>[44] Apoptosis resistance in fibroblasts precedes progressive scarring in pulmonary fibrosis and is
                    partially mediated by Toll-like receptor 4 activation, Toxicological Sciences, 2019, Kelly M. Hanson
                    et al., <a href="https://doi.org/10.1093/toxsci/kfz103">10.1093/toxsci/kfz103</a></p>
                <p>[45] Bet v 1 contiguous overlapping peptides anchored to virosomes with TLR4 agonist enhance
                    immunotherapy efficacy in mice, Clinical &amp; Experimental Allergy (51:339-349), 03-2021, Sabi
                    Airouche et Al, <a href="https://doi.org/10.1111/cea.13814">10.1111/cea.13814</a></p>
                <p>[46] Monophosphoryl lipid A prevents impairment of medullary thick ascending limb HCO3⁻ absorption
                    and
                    improves plasma HCO3⁻ concentration in septic mice, American Journal of Physiology - Renal
                    Physiology
                    (315: F711–F725), 05-2018, Bruns A. Watts 3rd et Al, <a
                        href="https://doi.org/10.1152/ajprenal.00033.2018">10.1152/ajprenal.00033.2018</a></p>
                <p>[47] Pretreatment with a novel Toll-like receptor 4 agonist attenuates renal ischemia-reperfusion
                    injury, American Journal of Physiology - Renal Physiology (324: F472-F482), 03-2023, Antonio
                    Hernandez
                    et al., <a href="https://doi.org/10.1152/ajprenal.00248.2022">10.1152/ajprenal.00248.2022</a></p>
                <p>[48] A TLR4 agonist liposome formulation effectively stimulates innate immunity and enhances
                    protection
                    from bacterial infection, Innate Immunity (29(3-4)), 03-2023, Jodi F. Hedges et al., <a
                        href="https://doi.org/10.1177/17534259231168725">10.1177/17534259231168725</a></p>
                <p>[49] The role of MyD88- and TRIF-dependent signaling in monophosphoryl lipid A-induced expansion and
                    recruitment of innate immunocytes, Journal of Leukocyte Biology (Volume 100, December 2016), Antonio
                    Hernandez et al., <a href="https://doi.org/10.1189/jlb.1A0216-072R">10.1189/jlb.1A0216-072R</a></p>
                <p>[50] Theu-defensin retrocyclin 101 inhibits TLR4- and TLR2-dependent signaling and protects mice
                    against influenza infection, Journal of Leukocyte Biology (102:000–000), 07-2017, Daniel Prantner et
                    Al, <a href="https://doi.org/10.1189/jlb.2A1215-567RR">10.1189/jlb.2A1215-567RR</a></p>
                <p>[51] D-allose Inhibits TLR4/PI3K/AKT Signaling to Attenuate Neuroinflammation and Neuronal Apoptosis
                    by
                    Inhibiting Gal-3 Following Ischemic Stroke, Biological Procedures Online (25:30), 2023, Yaowen Luo
                    et
                    Al, <a href="https://doi.org/10.1186/s12575-023-00224-z">10.1186/s12575-023-00224-z</a></p>
                <p>[52] Necroptosis: A Novel Pathway in Neuroinflammation, Frontiers in Pharmacology (Volume 12),
                    07-2021,
                    Ziyu Yu et Al, <a href="https://doi.org/10.3389/fphar.2021.701564">10.3389/fphar.2021.701564</a></p>
                <p>[53] Toll-Like Receptor 3 Activator Preconditioning Enhances Modulatory Function of Adipose-Derived
                    Mesenchymal Stem Cells in a Fully MHC-Mismatched Murine Model of Heterotopic Heart Transplantation,
                    Annals of Transplantation (25), 05-2020, Zhiye Bao et Al, <a
                        href="https://doi.org/10.12659/AOT.921287">10.12659/AOT.921287</a></p>
                <p>[54] Adult Aortic Valve Interstitial Cells Have Greater Responses to Toll-Like Receptor 4
                    Stimulation,
                    Annals of Thoracic Surgery (99, Issue 1), 01-2015, Xin-Sheng Deng et Al, <a
                        href="https://doi.org/null">null</a></p>
                <p>[55] Serine-/Cysteine-Based sp2‑Iminoglycolipids as Novel TLR4 Agonists: Evaluation of Their
                    Adjuvancy
                    and Immunotherapeutic Properties in a Murine Model of Asthma, Journal of Medicinal Chemistry (66,
                    4768−4783), 03-2023, Manuel González-Cuesta et Al, <a
                        href="https://doi.org/10.1021/acs.jmedchem.2c01948">10.1021/acs.jmedchem.2c01948</a></p>
                <p>[56] Immunomodulatory Response of Toll-like Receptor Ligand −Peptide Conjugates in Food Allergy, ACS
                    Chemical Biology (Vol. 16, Issue 11), 11-2021, Jorge Losada Méndez et Al, <a
                        href="https://doi.org/10.1021/acschembio.1c00765">10.1021/acschembio.1c00765</a></p>
                <p>[57] Targeting toll-like receptor 4 to modulate neuroinflammation in central nervous system
                    disorders,
                    Expert Opinion on Therapeutic Targets, 10-2019, Gunnar R Leitner et al, <a
                        href="https://doi.org/10.1080/14728222.2019.1676416">10.1080/14728222.2019.1676416</a></p>
                <p>[58] Selective serotonin reuptake inhibitor attenuates the hyperresponsiveness of TLR2+and
                    TLR4+Th17/Tc17-like cells in multiple sclerosis patients with major depression, Immunology (162,
                    290–305), 10-2020, Marisa C. Sales et al., <a
                        href="https://doi.org/10.1111/imm.13281">10.1111/imm.13281</a></p>
            </main>
        </div>
    );
}
